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The natural products from an un-identified Scleroderma sp. and Leptoscyphus expansus 
(Lehm.) Grolle were studied. A total of five known compounds were isolated from 
Scleroderma sp. Of the five compounds isolated, four were pulvinic acid derivatives 
which were responsible for the distinctive colour of the fungus. The four pulvinic acid 
derivatives are methyl-4,4’-di-O-methylatromentate (56), methyl per-O-methyl-4E-
atromentate (57), methyl per-O-methyl-4Z-atromentate (58) and methyl 3’,5’-dichloro-
4,4’-di-O-methylatromentate (66). The fifth compound from this fungus was a 
triterpenoid, (22R,23E)-22-Acetoxylanosta-8,23-diene-3α,25-diol (70). All of these 
compounds have been reported from an unknown species of Lycoperdon sp. These results 
showed that the two fungi share similar biosynthesis pathway despite the fact that they 
are from two different families. A total of seven compounds were isolated from the 
liverwort Leptoscyphus expansus (Lehm.) Grolle. Five of these were known flavones, all 
of which were reported elsewhere and they show bioactivities against various diseases. 
The flavones are 5-hydroxyl-7-methoxyflavone (92), 5-hydroxy-7,4’-dimethoxyflavone 
(95), 5,7-dimethoxyflavone (97), 5-hydroxy-6, 7-dimethoxyflavone (98) and 5, 6, 7-
trimethoxyflavone (Baicalein trimethyl ether) (102). A Chromene, methyl 5, 7-
dihydroxy-2, 2-dimethyl-2H-chromene-6-carboxylate (103) and a bibenzyls,  2, 2-
dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) chromene (108) were also isolated 
from the liverwort.  
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Chapter 1 General Introduction 
 
The origin, properties and purpose of natural product has fascinated researchers for many 
years. For centuries, drugs were entirely of natural origin and composed of herbs, animal 
products, and inorganic materials. Early remedies were mostly derived from plant 
(herbs). Natural drugs derived from microorganisms have a much shorter history, and 
their major impact on medicine goes back only about 60 years to the introduction of the 
antibiotic penicillin. Since then microorganisms have played an important part in natural 
product chemistry. Despite of this fact, plants still form the most important sources of 
natural product-derived drugs. Fungi and marine organism have also received attention 
from researchers and represent new sources of natural products. Natural products are 
generally divided into two broad classes, primary metabolites and secondary metabolites. 
 
1.2 Primary Metabolites and Secondary Metabolites 
Primary metabolites comprise molecules that are essential for life; principally proteins, 
carbohydrates, fats and nucleic acids, and these molecules are produced by metabolic 
pathways common to most organisms. Thus these common metabolic pathways 
demonstrate the fundamental unity of all living matter. For example, the Krebs cycle is 
utilized by most organisms to produce energy in the form of adenosine triphosphate 
(ATP) [1], whereas photosynthesis is used by all green plants to produce food (glucose) [2]. 
The study of primary metabolites (catabolism and anabolism) is known as biochemistry. 
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Secondary metabolites are found in only specific organisms, or groups of organisms, and 
are an expression of the individuality of species [3]. Thus, secondary metabolites are of 
limited distribution and some of them are unique to specific species. Secondary 
metabolites are not necessarily produced under all conditions, and in the vast majority of 
cases the function of these compounds and their benefit to the organism is not yet known. 
Secondary metabolites are usually not essential for the survival of the producing 
organism; however, some of them are nevertheless produced with specific purpose. For 
example, cinnamolide (1) is produced by the mollusk Dendrodoris denisoni as a 
defensive, predator deterrent metabolite [4]. Some of the secondary metabolites are 
produced at specific development periods of the life cycle. These include metabolites 
made during starvation (e.g. carbapenem antibiotics produced by Pseudomonas bacteria), 
in development (e.g. antibiotics made when Streptomycetes enter cellular differentiation 
pathways), and signaling (such as quorum-sensing molecules biosynthesized at particular 





The study of secondary metabolites is known as natural product (NP) chemistry, which 




1.2 The Building Blocks 
The extremely diverse structures of natural products seem confusing to the beginners. 
Fortunately, there are only a few building blocks which are employed in the biosynthesis 
of NPs. This demonstrates the fundamental unity of all living organism. The most 
important building blocks are acetyl coenzyme A (acetyl-CoA) (2), shikimic acid (3), 
mevalonic acid (4), and 1-deoxyxylusose 5-phosphate (5). These building blocks are 
actually produced from primary metabolic pathway and shunted into the secondary 
pathways when a particular metabolic channel is opened. They are employed respectively 
in the acetate, shikimate, mevalonate and deoxyxylusose phosphate pathways [3]. 
 
Important natural products formed from acetate pathway include phenolic compound 
[e.g. orsellinic acid (6)], prostaglandins [e.g. prostaglandin PGF2α (7)] and various fatty 
acids. On the other hand, the shikimate pathway leads to a variety of phenols [e.g. ferulic 
acid (8)], cinnamic acid (9), lignins and alkaloids. The mevalonate and deoxyxylulose 
phosphate pathways are together responsible for the biosynthesis of a vast array of 
























































In addition to acetyl-CoA, shikimic acid, mevalonic acid, and deoxyxylulose phosphate, 
other building blocks based on amino acids are frequently employed in NP biosynthesis. 
Examples include the alkaloid laburnine (13) and the tripeptide (14) (precursor of many 

















It is not always possible to categorize NPs according to a single key intermediate 
employed for their construction, because many NPs use two or even more basic building 
blocks [5]. These compounds are said to be of mixed biosynthetic origin and examples 
include lysergic acid (15) (shikimic acid and terpenoid origin) and the insecticide 
rotenone (16) (acetyl CoA, shikimic acid and terpenoid origin). This is advantageous 
























1.3 Natural Products as Drug Leads 
For thousands of years medicine and natural products (NPs) have been closely linked 
through the use of traditional medicines and natural poison [6]. Some of the plant derived 
NPs used as early medicine are aspirin (17), morphine (18), quinine (19), and pilocarpine 
(20) [6-7]. Aspirin and morphine are used as pain killers. Unfortunately, morphine also 
induces a state of euphoria and mental detachment, together with nausea, vomiting, 
constipation, tolerance, and addiction. On the other hand, quinine has been used for many 
years in the treatment of malaria; whereas pilocarpine is used in eyedrops as miotics 
(miotic is a substance that causes the constriction of pupil of the eye) and for the 




























NPs still played an important role in the development of new drugs despite the advent of 
new synthetic tools. Of the 877 small-molecule New Chemical Entities (NCE) introduced 
between 1981 and 2002, roughly half (49%) were NPs, semi-synthetic NP analogues or 
synthetic compounds based on NP pharmacophores [8] [a pharmacophore is the ensemble 
of steric and electronic features that is necessary to ensure optimal interactions with a 
specific biological target structure and to trigger (or to block) its biological response]. 
NP-derived drugs are well represented in the top 35 worldwide selling ethical drug sales 
of 2000, 2001, and 2002 [9]. Shu (1998) reported that NP-derived drugs were well 
represented in the anticancer, anti-infective, immunosuppression, and neurological 
disease therapeutic areas and some of these compounds have progressed further into 
clinical trials or onto the market [10]. All these facts highlight the importance of NPs as 
drug leads which cannot be substituted by synthetic compounds. 
 
 
1.4 Current State of Industrial Natural Product Research 
Despite the wide use of NPs as drugs in various disease area, pharmaceutical research 
into NPs has experienced a slow decline during the past two decades [9, 11], which is 
probably due to the nature of the drug discovery process. Drug discovery is a difficult and 
expensive process. The amount of money currently being invested in R&D and clinical 
development has increased drastically, but the output of newly launched drugs has fallen 
[12]. This has led many big pharmaceutical companies to find an alternative method which 
is more effective and efficient in the hope of substituting the NP research. Many big 
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pharmaceutical companies have terminated or significantly scaled down their natural 
product operations in the last 10 years [13-15]. 
 
From 1990-1996, there have been 10 new natural product templates discovered that have 
compounds in clinical investigation or registration [23]. However, no new templates/novel 
structures have been discovered since 1996 that have resulted in compounds entering 
clinical trials. As a consequence, most natural product and NP-derived drugs currently in 
clinical trials are derived from relatively old templates. The small number of new NP 
templates discovered over the last 10 years coincides with a significant reduction in the 
screening of NPs by the pharmaceutical industry as well as the development of 
combinatorial chemistry. 
 
The development of combinatorial chemistry, which is capable of generating libraries 
consisting of millions of compounds and thus increases the chance of finding drug leads 
faster, has created huge excitement among big pharmaceutical companies, which quickly 
changed their drug discovery process to include a significant proportion of combinatorial 
chemistry [9]. However, results from early combinatorial libraries were often 
disappointing. These big combinatorial libraries achieve only low hit rate or no hit at all. 
The lack of lead compounds from synthetic libraries in therapeutic areas such as anti-
infective, immunosuppression, oncology, and metabolic diseases may be due to the 
different chemical space occupied by NPs and synthetic compounds. The combinatorial 
libraries were designed on the basis of chemical accessibility and maximum achievable 
size rather than on biologically relevant chemical diversity or properties [22]. Despite the 
 9
failure of combinatorial chemistry in creating a biological relevant library, it is 
undoubtedly a powerful tool for creating huge library in a short period of time. 
Combinatorial chemistry is mainly used now for lead optimization and the generation of 
focused compound libraries [16]. 
 
NP research should not be totally substituted. It should be incorporated into a well-
balanced drug discovery program. NPs are currently used as starting templates in the 
synthesis of combinatorial libraries. Furthermore, NP pharmacophores are well 
represented in lists of “privileged structures”, which makes them ideal candidates for 
building blocks for biologically relevant chemical libraries [17]. NPs can be viewed as a 
population of privileged structures (chemical scaffolds that promote binding to multiple 
target proteins) selected by evolutionary pressures to interact with a wide variety of 
proteins and other biological targets for specific purposes [11]. NPs have been a major 
source of new drugs, and many successful drugs were originally synthesized to mimic the 
action of molecules found in nature. 
 
There is a current resurrection of natural product research in the hope of finding new drug 
leads. At least 21 NP and NP-derived drugs have been launched onto the market in the 
United States, Europe or Japan from 1998-2004.  The 21 drugs can be classified as 3 





1.5 Natural Products versus Synthetic Compounds 
It has long been recognized that natural product structures have the characteristics of high 
chemical diversity, biochemical specificity and other molecular properties that make 
them favourable as lead structures for drug discovery, and which serve to differentiate 
them from libraries of synthetic and combinatorial compounds [18]. NPs-derived drugs 
[e.g. Taxol (21) and Rapamycin (22)] show structural difference from that of the 
synthetic drugs [e.g. Viagra (23) and Prozac (24)] [24]. 
 
Studies reveal that natural products typically have a greater number of chiral centres and 
increased steric complexity than either synthetic drugs or combinatorial libraries [19, 20]. In 
many cases, the presence of such chiral centers contributes to the selectivity of these 
molecules for their predominantly stereospecific binding sites [19]. Besides that, synthetic 
compound tend to contain a significantly higher number of nitrogen-, sulphur- and 
halogen-containing groups; whereas natural products bear a higher number of oxygen 
atoms [19, 21]. These are likely to have important consequences for the interaction with 
binding sites. This is particularly significant in the context of the evolution of receptor-
ligand interaction. Oxygen and hydroxyl group play an especially important role in this 
regard, since they can act as both donor and receptor [19]. Hence NPs show greater 
bioactivity as compared to synthetic compounds. Furthermore, NP libraries also have a 
broader distribution of molecular properties such as molecular mass, octanol-water 
partition coefficient and diversity of ring systems compared with synthetic and 
combinatorial counterpart [19, 21]. NPs show greater lipophilicity as compared to synthetic 
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compound [19]. Thus, NPs can be absorbed easily through the intestine and as well as 





















































1.6 NPs and NP-Derived Drugs in Various Disease Area 
NPs and NP-derived drugs play an important role in curing diseases. They have been 
used to cure infectious disease, neurological disease, cardiovascular and metabolic 
disease, immunological and inflammatory disease, and most importantly the oncological 
disease [23]. 
 
For infectious disease, NPs and NP-derived drugs are used as antibacterial, antifungal, 
antiparasitic and antiviral drugs [23]. Ceftobiprole (BAL-5788) (25) and tetracycline (26) 
are used as antibacterial drugs. Ceftobiprole is developed as a prodrug and is used as a 
broad spectrum antibiotic with activity against both Gram-positive and negative bacteria. 
It is in Phase III development and has potent bactericidal activity against methicillin 
resistant Staphylococcus aureus (MRSA) and penicillin resistant Streptococcus 
pneumoniae
 [25]. Tetracycline on the other hand displays activity against both Gram 
positive and negative bacteria by binding reversibly to the 30S bacterial ribosome and 
effectively halting protein synthesis. Unfortunately, bacteria have gained resistance to it. 
The most common causes of tetracycline resistance are bacterial efflux and ribosome 
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protection. There is effort to develop new generation of tetracycline that have more 
potent antibacterial activity and undergo less bacterial efflux [26]. 
 
Most antifungal drugs in use today have some connection to NPs [23]. Icofungipen (PLD-
118) (27) is used as an antifungal drug. 27 is a NP-derived synthetic compound in Phase 
II clinical trials whose structure is based upon the cyclic β-amino acid cispentacin (28). It 
inhibits fungal growth through intercellular accumulation and the disruption of fungal 
protein synthesis through the inhibition of isoleucyl-tRNA synthetase [27]. Phase II study 
shows that 27 is likely to be safe and effective in human immunodeficiency virus (HIV)-
infected patients with oropharyngeal candidiasis [23]. 
 
In the case of anti-parasitic drug, Fumagillin (SR-90144) (29) was granted EU orphan 
drug status to treat intestinal microsporidiosis in March 2002 [28]. Microsporidiosis is 
caused by the spore-forming unicellular parasite Enterocytozoon bieneusi and is of major 
concern to immunocompromised patients in who it causes chronic diarrhea. On the other 




Some of the greatest health risks known to humans are caused by viral diseases such as 
HIV, hepatitis B and C, Ebola, influenza, dengue fever and yellow fever. In 1992, 
workers at the National Cancer Institute (NCI), a branch of the US National Institutes for 
Health, reported the isolation of coumarins, calanolide A (31) with potent activity against 
HIV-1 from the tree, Calophyllum lanigerum, collected in Sarawak, Malaysia [30]. 
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Calonolide A was also found to have activity against all Mycobacterium tuberculosis 
strains tested. This property is unique amongst antiviral agents and may allow more 
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Some of the earliest NP derived drugs used for the treatment of pain and central nervous 
system (neurological disease) diseases include the opiate alkaloids from the opium 
poppy, Papaver somniferum, ergot from the fungus, Claviceps purpurea, and the tropane 
alkaloids like cocaine from the South American plant, Erythroxylon coca [31]. Morphine 
(18) is one of the major alkaloids of the opium poppy, Papaver somniferum, and has been 
used as an analgesic and narcotic for thousands of years. Capsaicin (32) is the compound 
that cause the burning sensation associated with eating of chilies. Capsaicin-based creams 
and patches are available for topical use to relieve pain associated with conditions such as 
osteoarthritis, post-herpetic neuralgia, psoriasis and diabetic neuropathy [32]. Phenserine 
(33) which is an acetylcholinesterase (AChE) and beta amyloid precursor protein 
inhibitor is developed to treat mild to moderate Alzheimer’s disease. None of the AChE 
inhibitors presently on the market reduce the levels of beta amyloid precursor protein 
and, as a consequence, 33 may represent an important new treatment for Alzheimer’s 
disease if approved [33]. The immunosuppressant cyclosporine A (34) has potent 
neuroprotective properties in stroke, trauma and neurodegeneration by prevention or 
reduction of neuron cell death by the inhibition of critical enzymes and free radicals and 
protecting the mitochondria. It also shows promise in the treatment of Alzheimer’s 













































NPs have made a major impact in the treatment of cardiovascular and metabolic diseases. 
Ruboxistaurin (LY333531) (35) is a competitive inhibitor of adenosine triphosphate 
(ATP) binding to protein kinase C developed for the treatment of microvascular 
complications in patients with diabetes mellitus [35]. 
 
NPs have played a pivotal role in the development of most immunosuppressive drugs 
(Table 1). Aspirin (17) is one of the most famous NP-derived drugs that was discovered 
in the late 1890s and is still used widely as an analgesic and anti-inflammatory [3]. Other 
important anti-inflammatory drugs used in controlling asthma are the corticosteroids and 
salbutamol.  FTY720 (36) is a new immunosuppressant which is currently in Phase III 
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clinical trials for use in transplantation, autoimmune diseases and multiple sclerosis [36]. 
36 exerts its immunosuppressive activity after phosphorylation in vivo by sphingosine 
















Table 1 Natural product derived immunosuppressant drugs [23] 




















Based on bacterial metabolite spergualin 
Semi-synthetic derivative of mycophenolic acid 
Actinomycetes metabolite 
Fungal metabolite 
Semi-synthetic derivative of sirolimus 
 
  
Newman, Cragg and Snader analyzed the number of NP-derived drugs present in the total 
drug launches from 1981-2002 and found that NPs were a significant source of these new 
drugs, especially in the oncological therapeutic areas [6]. NPs and NP-derived compounds 
in clinical development for oncology are mainly from three sources: plant, 
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microorganism and marine organism. Some of the NPs and NP-derived drugs with anti-
cancer properties are presented in Table 2.  
 
Table 2 Oncology Drugs derived from plant, microorganism and marine organism [23] 
Name (Synonym) Mechanism of Action Development status 
Plant derived compounds 
Exatecan (DX-891f) (37) 
XRP-9881 (RPR-109881A) (38) 
Vinflunine ditartrate (Javlor®) (39) 
 
Microorganism derived compounds 
Suberoylanilide hydroxamic acid (40) 
Ixabepilone (BMS-247550) (41) 
 
Marine derived compounds 
Discodermolide (42) 








































































































































































Chapter 2 Chemistry of an unidentified Scleroderma sp. 
2.1 Introduction 
Scleroderma sp., otherwise known as “earthballs” or “poison puff balls”, occur as ecto-
mycorrhizal associates of a wide range of trees, including oak and eucalyptus [37], or as 
saprotrophs in soil or rotting wood [38]. The fruiting bodies are formed at the surface of 
the soil, or just below, and are reminiscent of a potato in appearance. They have a brown 
outer peridium and when the spores are mature a dark, blackish purple interior. 
Scleroderma. belongs to the family Sclerodermataceae. The family Sclerodermataceae is 
distinguished by the following features (from the puffballs in Lycoperdaceae and from 
other groups) [39]: 
1. Fruiting body matures above the surface (epigeous).  
2. There is no stipe (stem or stalk-like structure supporting the cap of a mushroom) 
but the base of some species is slightly extended or may have a stipe-like 
rhizoidal mass below the sporocarp (spore producing organ).  
3. The gleba (internal spore-producing mass) becomes dry and powdery without 
going through a gooey stage. Basidia occur in groups throughout the gleba and do 
not mature simultaneously.  
4. The immature gleba is firm to hard, not soft.  
5. The gleba is soon colored, in contrast to Lycoperdaceae which become colored 
slowly.  
6. Pseudo-columella is rare. It does not occur if peridium opens stellately.  
7. There are several microscopic features in which the two families differ, relating to 
hymenium and capillitium. 
 22
About 25 species of Scleroderma have been described worldwide, and at least four 
species are known to be poisonous: S. albidum, S. areolatum, S. cepa, and S. citrinum [38]. 
Symptoms of poisoning can occur within an hour of eating and include loss of 
consciousness, nausea, severe abdominal pains, vomiting, perspiration, generalized 
tingling sensations, spasms, cramps, paralysis, and anaphylactic shock [37,40]. It has been 
reported that the spores of S. citrinum possess some anti-inflammatory property and its 
mycorrhiza enhance the growth of the plant which it has parasitized [41].  
 
The chemistry of the “earthballs” has not, however, been well studied [40]. Among all the 
Scleroderma, the chemical constituents of S. citrinum are well studied. Some of the 
chemical constituents isolated from S. citrinum are norbadione A (44), badione A (45), 
xerocomic acid (46), variegatic acid (47) sclerocitrin (48), (20S,22S,23E)-22-O-acetyl-
25-hydroxylanosta-8,23(E)-diene-3-one (49), methyl 4,4’-dimethoxyvulpinate (50) and 




























44, n = 0       46 

















































50, R = CH3 
51, R = H 
 
 
2.2 Biosynthesis of pulvinic acid derivatives 
Pulvinic acid derivatives are the major chemical constituents isolated from the genus 
Scleroderma. It is these pigments that cause the distinctive colour of the fungus. A brief 
description of their biosynthesis is given below. The biosynthesis of fungal pulvinic acid 
derivatives follows the same general course as was previously established for lichens [59]. 
Tyrosine (52) is converted to 53 which will then condense with another molecule of 53 to 
yield atromentin (54a). 54a is then oxidised to yield an intermediate 54b, which 
undergoes intramolecular condensation to yield the product atromentic acid (55) (see 
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Figure 1). 55 can be further modified by hydration and methylation to create a range of 













































2.3 Results and Discussion 
The chemistry of the fungi in the genus Scleroderma has been studied previously. 
However, there may be new constituents that have not been reported from this fungus. 
The chemistry of an unidentified Scleroderma sp. was investigated in this study in the 
hope of finding new chemical entities. 
  
The MeOH extract of an unidentified Scleroderma sp. afforded four known pulvinic acid 
derivatives, methyl-4,4’-di-O-methylatromentate (56), methyl per-O-methyl-4E-
atromentate (57), methyl per-O-methyl-4Z-atromentate (58) and methyl 3’,5’-dichloro-
4,4’-di-O-methylatromentate (66), and one triterpenoid (22R,23E)-22-Acetoxylanosta-
8,23-diene-3α,25-diol (70). The identifications of the compounds were done by 
comparing the 1H, 13C, UV and IR spectral data with those of the authentic samples. All 
the compounds isolated from this fungus have been previously reported from an 
unidentified Lycoperdon sp. [113]. These results imply that the two fungi share similar 
biosynthetic pathway although they are from two different families (Scleroderma sp. 
from the family Sclerodermataceae and Lycoperdon sp. from the family Lycoperdaceae). 









Compound 56 was obtained as an orange solid. It is one of the major components occur 
throughout the genus Scleroderma. It was not phenolic since it showed negative alcoholic 
ferric chloride test. Its UV spectrum exhibits absorption bands at 230, 260, 305 and 385 
nm and its IR spectrum showed strong bands for hydroxyl group [3547 cm-1 (OH)], 
benzene rings (1600, 1513, 1456 cm-1) as well as γ-lactone (1770 cm-1) and unsaturated 




















The 1H and 13C NMR spectra (see Table 3) contain signals for an ester group [δH 3.89 
(3H, s, 6-OCH3); δC 171.79 (C-6) and 54.36 (6-OCH3)], a γ-lactone carbonyl [δC 166.13 
(C-1)], an enolic hydroxyl proton [δH 13.56 (1H, s, 3-OH)], two para-disubstituted 
benzene rings [δH 8.13 (2H, d, J = 9.06 Hz, H-2’ and H-6’), 7.20 (2H, d, J = 8.7 Hz, H-8 
and H-12), 6.96 (2H, d, J = 9.06 Hz, H-3’ and H-5’) and 6.94 (2H, d, J = 8.7 Hz, H-9 and 
H-11); δC 129.23 (2×, C-2’ and C-6’), 131.37 (2×, C-8 and C-12), 113.82 (2×, C-3’ and 
C-5’) and 113.47 (2×, C-9 and C-11)], two non ortho-disubstituted methoxyl groups [δH 
3.82 (6H, s, 4’-OCH3 and 10-OCH3); δC 55.19 (2x, 4’-OCH3 and 10-OCH3)] and eight 
substituted sp2 carbons, four of which are oxygenated. Therefore the compound has 
thirteen units of unsaturation which can be accounted for by two benzene rings, an ester, 
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a lactone and two C—C double bonds. These data are consistent with a pulvinic acid 
ester structure. The upfield shift of C-3’ and C-5’ of ring A and C-9 and C-11 of ring C 
indicating that C-4’ and C-10 are methoxylated.  This is supported by the occurrence of 
two para-substituted benzene rings. This leads to structure 56 commonly known as 
methyl-4,4’-di-O-methylatromentate. Thus, it has the molecular formula of C21H18O7. 
The occurrence of the two methoxyl groups at the same 1H chemical shift (3.82 ppm) is 
just coincident. The molecule is not symmetrical. This is further supported by the 
occurrence of two separate peaks for C-4’ (δC 159.60) and C-10 (δC 159.40) in 
13C NMR 
spectrum. The identity of 56 is further supported by its UV, IR and 1H NMR data with 
those reported for methyl-4,4-di-O-methylatromentate [47,51,52,53]. 56 has been isolated 
previously from an unknown Malaysian species Scleroderma sp. and Scleroderma 
citrinum [43, 47, 50]. It was also reported as a synthetic product [53]. 
 
The bioactivity of 56 has been previously reported elsewhere. 56 exhibited antitubercular 
activity against M. tuberculosis (IC50 = 25 µg/ml) although it is not as potent as the 
reference substances isoniazide (IC50 = 0.04-0.09 µg/ml) and kanamycin sulfate (IC50 = 
2.0-5.0 µg/ml) [43]. In another study, Foden et al. (1975) showed that 56 is active against 
rat arthritis with IC50 of 25 mg/kg, which is comparable to the reference compound 
phenylbutazone (IC50 = 20 mg/kg)
 [49]. However, the mechanism of its bioactivities is still 
unknown. 
 
56 was biosynthesized from pulvinic acid skeleton by methylation of the carboxylic 
group and two phenol groups using three molecules of S-adenosylmethionine (SAM) as 
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shown in Figure 2 (see Figure 1 for biosynthesis of pulvinic acid; see Figure 2 for 





















Table 3 1H (300 MHz) and 13C (75 MHz) NMR data for methyl 4,4’-di-O-
methylatromentate (56) in CHCl3. (J in Hz in parentheses) 






























7.20 d (8.7) 
6.94 d (8.7) 
-- 
6.94 d (8.7) 
7.20 d (8.7) 
-- 
8.13 d (9.06) 
6.96 d (9.06) 
-- 
6.96 d (9.06) 





























Methyl per-O-methyl-4E-atromentate (57) 
Compound 57 was obtained as a yellow solid. There are two UV absorption maxima at 
235 and 363 nm and it has similar IR spectral features to those of 56 suggesting that it 
also contain benzene ring [1600, 1510, 1461 cm-1], a γ-lactone [1768 cm-1 (C=O)] and an 
unsaturated ester group [1732 cm-1 (C=O), 1255 and 1050 cm-1 (C-O)]. The absence of 





















The 1H and 13C spectra of 57 (see Table 4) showed similarity with that of 56, suggesting 
that they may be analogues. There is an ester group [δH 3.76 (3H, s, 6-OCH3); δC 167.99 
(C-6) and 52.63 (6-OCH3)], a γ-lactone [δC 167.27 (C-1)], two para-disubstituted benzene 
rings [δH 7.64 (2H, d, J = 8.90 Hz, H-2’ and H-6’), 6.93 (2H, d, J = 8.90 Hz, H-3’ and H-
5’), 7.48 (2H, d, J = 8.7 Hz, H-8 and H-12) and 6.97 (2H, d, J = 8.7 Hz, H-9 and H-11); 
δC 130.68 (2×, C-2’ and C-6’), 130.93 (2×, C-8 and C-12), 114.23 (2×, C-3’ and C-5’) 
and 113.93 (2×, C-9 and C-11)], three methoxyl groups [δH 3.89 (3H, s, 3-OCH3), 3.82 
(6H, s, 4’-OCH3 and 10-OCH3); δC 60.85 (3-OCH3), 55.35 (2×, 4’-OCH3 and 10-OCH3)] 
and eight substituted sp2 carbons, four of which are oxygenated. Therefore the compound 
has thirteen units of unsaturation which can be accounted for by two benzene rings, an 
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ester, a lactone and two C—C double bonds. The only obvious difference between 57 and 
56 is the absence of the signal for a deshielded enolic hydroxyl proton. This is also 
supported by the absence of hydroxyl peak in IR spectrum. Instead, the resonance for a 
methoxyl group is observed at δH 3.89. It is apparent that the enolic hydroxyl in 56 is 
substituted by the methoxyl group in 57. Thus 57 is postulated as methyl per-O-methyl-
4E-atromentate. It has the molecular formula of C22H20O7. Later examination of the 
literature confirmed the postulation. The 1H, 13C NMR, UV and IR spectral data of 57 are 
identical to those reported for methyl per-O-methyl-4E-atromentate [44, 54]. 57 has been 
previously reported from Scleroderma citrinum, Clitocybe illudens, Xerocomus badius 
and an unknown Malaysian species of Scleroderma sp [43, 44, 47, 50, 54]. 
 
57 is also a pulvinic acid derivative. It is formed by methylation of the carboxylic group, 
two phenol groups and an enolic hydroxyl group of pulvinic acid by four molecules of S-


























Table 4 1H (300 MHz) and 13C (75 MHz) NMR data for methyl per-O-methyl-4E-
atromentate (57) in CHCl3. (J in Hz in parentheses) 






























7.48 d (8.7) 
6.97 d (8.7) 
- 
6.97 d (8.7) 
7.48 d (8.7) 
- 
7.64 d (8.90) 
6.93 d (8.90) 
- 
6.93 d (8.90) 







































Methyl per-O-methyl-4Z-atromentate (58) 
This compound was obtained as a yellow oil. The IR spectrum showed the presence of a 
γ-lactone [1772 cm-1 (C=O)], an unsaturated ester group [1728 cm-1 (C=O), 1250 and 




















The 1H and 13C NMR spectra of 58 (see Table 5) show the presence of an ester group [δH 
3.85 (3H, s, 6-OCH3); δC 167.12 (C-6) and 52.81 (6-OCH3)], a γ-lactone [δC 166.32 (C-
1)], two para-disubstituted benzene rings [δH 7.57 (2H, d, J = 8.90 Hz, H-2’ and H-6’), 
6.95 (2H, d, J = 8.90 Hz, H-3’ and H-5’), 7.34 (2H, d, J = 8.70 Hz, H-8 and H-12) and 
6.90 (2H, d, J = 8.70 Hz, H-9 and H-11); δC 130.90 (2×, C-2’ and C-6’), 131.31 (2×, C-8 
and C-12), 114.01 (2×, C-3’ and C-5’) and 113.43 (2×, C-9 and C-11)], three methoxyl 
groups [δH 3.34 (3H, s, 3-OCH3), 3.84 (6H, s, 4’-OCH3 and 10-OCH3); δC 60.31 (3-
OCH3), 55.33 (2×, 4’-OCH3 and 10-OCH3)] and eight substituted sp
2 carbons, four of 
which are oxygenated. Therefore the compound has thirteen units of unsaturation which 
can be accounted for by two benzene rings, an ester, a lactone and two C—C double 
bonds. The 1H and 13C spectra of 58 are very similar to those of 57, suggesting that 58 
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must be an isomer of 57. The only obvious difference between compound 58 and 57 is 
that, the C-3 methoxyl group in 58 is more shielded than that in 57. So, the C-3 methoxyl 
in 58 (δH 3.34) appeared at higher field than that in 57 (δH 3.89). The E-isomer (57) 
displays a distinct and characteristic low field methoxyl methyl resonance at δH 3.89, 
which is associated with the methyl tetronate methyl group deshielded by the 
neighbouring (cis to it) methoxycarbonyl group [58]. Furthermore C-4 in 58 has become 
more deshielded (δC 144.03) by ca. 4 ppm as compared to that in 57. Further examination 
of the 1H shift for C-3 methoxyl group of the Z-isomer of permethylated gomphidic acid 
(59) (δH 3.40), isogomphidic acid (60) (δH 3.39) and methyl leprapinate (61) (δH 3.31) 
confirmed that compound 58 is methyl per-O-methyl-4Z-atromentate [58]. Furthermore 
1H, 13C NMR, IR and UV spectral data of 58 are identical with those reported for methyl 
per-O-methyl-4Z-atromentate 113. This compound has been isolated previously from an 







































(59) R’ = OCH3, R” = H      (61) 




Table 5. 1H (300 MHz) and 13C (75 MHz) NMR data for methyl per-O-methyl-4Z-
atromentate (58) in CHCl3. (J in Hz in parentheses) 






























7.34 d (8.70) 
6.90 d (8.70) 
- 
6.90 d (8.70) 
7.34 d (8.70) 
- 
7.57 d (8.90) 
6.95 d (8.90) 
- 
6.95 d (8.90) 




























The biosynthesis of 58 Scleroderma sp. has not been studied. However, its synthetic 
pathway from its E-isomer has been reported [113]. Figure 4 shows the possible 
biosynthetic pathway of 58. The biosynthesis of 58 is the same as its E-isomer from 
tyrosine through atromentin (54a) to the intermediate 54b (see Figure 1). 54b undergoes 
a series of rearrangement to form the intermediate 62, which will then undergoes a 
rotation at C4—C5 bond to form the intermediate 63. 63 undergoes a series of 
rearrangement to form the intermediate 64, which will then undergoes intramolecular 























































Methyl 3’,5’-dichloro-4,4’-di-O-methylatromentate (66) 
This compound was obtained as a yellow solid. The EI-MS showed a base peak 
corresponding to [M-CH3OH]
+ at m/z 418 [C20H16Cl2O7, HREI-MS 418.0005]. The 
molecular ion m/z 450 (C21H16Cl2O7) was not shown in the mass spectrum. The IR 
spectrum showed the presence of a hydroxyl group [3530 cm-1 (OH)], a γ-lactone [1780 
cm-1 (C=O)], an unsaturated ester group [1680 cm-1 (C=O)] and benzene rings (1600, 























The 1H and 13C spectra of 66 (see Table 6) show signals for an ester group [δH 3.90 or 
3.97 (3H, s, 6-OCH3); δC 170.74 (C-6) and 54.62 (6-OCH3)], a γ-lactone [δC 165.68 (C-
1)], an enolic hydroxyl proton [δH 13.42 (1H, s, 3-OH)], a para-disubstituted benzene 
rings [δH 8.12 (2H, d, J = 9.11 Hz, H-2’ and H-6’), 6.97 (2H, d, J = 9.11 Hz, H-3’ and H-
5’); δC 129.51 (2x, C-2’ and C-6’), 114.13 (2x, C-3’ and C-5’)], two aromatic protons [δH 
7.19 (2H, s, H-8 and H-12)], two methoxyl groups, one of which is ortho-disubstituted 
[δH 3.85 (3H, s, 4’-OCH3) and 3.90 or 3.97 (3H, s, 10-OCH3); δC 55.28 (4’-OCH3), 60.72 
(10-OCH3)] and ten substituted sp
2 carbons, four of which are oxygenated. 
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The 1H and 13C spectra of 66 are very similar to those of 56. The only difference is that, 
there is only one para-substituted ring in 66 but two in 56. The presence of two 
equivalent unsubstituted aromatic carbons [δC 130.45 (C-8 and C-12)] and two equivalent 
fully substituted aromatic carbons [δC 129.13 (C-9 and C-11)] indicates that the second 
aromatic ring is symmetrically substituted.  
 
Mass spectrum of this compound shows the presence of a peak at m/z 418 (correspond to 
[M – CH3OH]
+) and its isotope peak at m/z 420 and 422 in an approximate relative 
abundance of 9:6:1 indicates that the molecule contains two chlorine atoms. This 
fragment peak is an indicative of formation of a dilactone peracetate (67) derivative 
through loss of MeOH from the parent compound. This phenomenon had been previously 
reported in other vulpinic acid derivatives [46]. Further examination of mass fragment, 1H, 
13C NMR, UV and IR spectral of 66 with those of  methyl 3’,5’-dichloro-4,4’-di-O-












Chlorinated pulvinic acids as natural products have been previously reported. These 
include methyl 3’-chloro-4,4’-di-O-methyl-4Z-atromentate (68) and 3’-chloro-3,4,4’-tri-
O-4Z-atromentate (69) [47, 48]. Many halogenated pulvinic acids derivatives have also 
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been synthesized for in vivo evaluation as potential anti-inflammatory agents [49]. 66 
however, has not been reported as a synthetic product [50]. 66 was found to show 
moderate inhibition of the bacteria, B. subtilis (an inhibition zone of 4 mm was observed 

















   68      69 
 
Biogenetic speculation upon similar Scleroderma products may suggest which 
compounds are more advanced and which are more primitive. It seems plausible that 
compounds requiring more steps in their synthesis are more advanced. An O-methylated 
derivative is more advanced than the compound of the identical structure that is not O-
methylated (e.g., the O-methylated pulvinic acid is more advanced than non-methylated 
pulvinic acid). But it does not follow that an O-methylated compound of one structure is 
necessarily more advanced than another structure that is not O-methylated. Chlorinated 
derivatives are more advanced than unchlorinated compounds of corresponding structure 
[55]. Thus, it followed that 57 is more advanced than 56, and 66 is more advanced than 56, 
57 and 58.  
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Table 6 1H (300 MHz) and 13C (75 MHz) NMR data for methyl 3’,5’-dichloro-4,4’-O-
methylatromentate (66) in CHCl3. (J in Hz in parentheses) 




































8.12 d (9.11) 
6.97 d (9.11) 
- 
6.97 d (9.11) 








































Compound 70 was obtained as a white solid. The EI-MS showed molecular ion [M]+ at 
m/z 500.0, consistent with the molecular formula C32H52O4, which is confirmed by HREI-
MS (found [M]+ at m/z 500.3864, requires 500.3866). Its IR spectrum has characteristic 





































The 1H NMR spectrum (see Table 7) shows signals for a trans disubstituted olefin group 
[δH 5.86 (1H, d, J = 15.60 Hz, H-24) and 5.62 (1H, dd, J = 7.75, 15.60 Hz, H-23)], two 
oxygenated methine protons, one of which is allylic [δH 5.30 (1H, dd, J = 3.45, 7.75 Hz, 
H-22) and 3.42 (1H, br s, H-3β)], an acetate [δH 2.05 (3H, s, CH3CO)], one secondary 
methyl [δH 0.94 (3H, d, J = 6.60 Hz, H3-21)] and seven tertiary methyl groups, two of 
which are attached to an oxygenated carbon [δH 1.32 (6H, s, H3-26 and H3-27), 0.98, 
0.97, 0.87, 0.83 and 0.70 (each 3H, s, CH3)]. The 
13C NMR spectrum showed nine 
methyls, eight methylenes, seven methines and eight quaternary carbons indicating the 
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presence of seven units of unsaturation. Since the two olefins and the acetate account for 
three of these and that the molecular formula is C32H52O4, the molecule must be 
tetracarbocyclic with a secondary and a tertiary alcohol. The presence of four rings and 
eight methyls (excluding the acetate methyl) suggests that the compound is a triterpenoid. 
The peaks at δC 134.87 and 133.86 are suggestive of the C-8 and C-9 ring olefinic 
carbons of a lanostane or euphane nucleus [114]. The other two sp2 methine carbons at δC 
142.09 (C-24) and 120.89 (C-23) are carbons of the side chain disubstituted olefin. With 
the observation of a 15.6 Hz coupling, the olefinic protons (H-23 and H-24) are trans to 
each other. One of the protons (H-23) further couples with a methine neighbour (H-22). 
In view of the deshielded nature of H-22 (δH 5.30), C-22 must bear the acetate group. The 
two methyls, H3-26 and H3-27 at δH 1.32 are deshielded suggesting their attachment to 
the fully substituted oxygenated carbon (δC 70.69, C-25) which must bear the tertiary 
hydroxyl group. The signal at δC 76.02 is attributed to the second hydroxyl group 
attached to C-3. The configuration of the hydroxyl group at C-3 is considered to be in α 
position because the chemical shift of the signal is δC 76.02 instead of δC 80.0 for β 
configuration of 3β,22,25-trihydroxylanosta-8-ene (71) and 3β-hydroxy-8,24-diene-
lanosta-21,23-lactone (72) [56, 57]. This configuration was supported by a very small value 
of coupling constant of H-3β at δH 3.42 (bs).  Comparison of its mass fragment, 
1H, 13C 
NMR and IR spectral with literature values [115] reveals that the compound is (22R,23E)-
22-Acetoxylanosta-8,23-diene-3α,25-diol (70). This compound has been isolated 














   71      72 
 
The bioactivities of this compound have not been studied yet. However, its 22S isomer, 
(22S,23E)-22-Acetoxylanosta-8,23-diene-3α,25-diol shows antioxidant free radical 















Table 7 1H (300 MHz) and 13C (75 MHz) NMR data for (22R,23E)-22-
Acetoxylanosta-8,23-diene-3α,25-diol (70) in CHCl3. (J in Hz in parentheses) 





















































0.94 d (6.60) 
5.30 dd (3.45, 7.75) 
5.62 dd (7.75, 15.60) 

















































2.4.1 General Experimental 
Chromatography 
Thin layer Chromatography (TLC) was carried out on precoated glass TLC plates—
normal phase (Merck, Kieselgel 60F254, 250 µm), C18 silica (Whatman, KC18F, 200 µm), 
DIOL silica (Merck, HPTLC-Fertigplatten DIOL F254S). Analytical TLC plates were 
visualized with UV light (254 nm) and then stained with I2 vapor or ethanolic FeCl3 (for 
detection of phenolic compounds). Column chromatography was carried out on silica gel 
(40-63 µm, Merck) or on C18 (25-40 µm, Merck) and DIOL (Merck, Lichroprep 40-63 
µm) bonded phases. For gel permeation column chromatography (GPC), Sephadex LH-
20 (MeOH:CH2Cl2 = 1:1 as eluent) was used.  
 
Spectroscopy 
UV spectra were obtained on a SHIMADZU 1601PC UV-Visible spectrophotometer. IR 
spectra were measured with the Varian Excalibur Series 3100 FT-IR. Electron impact 
(EI) mass spectra were obtained on a VG Micromass 7035 instrument at 70eV. Accurate 
mass electron impact (HR-EI) mass spectra were obtained on a Finnigan MAT95XL-T 
instrument at 20 KV with 3-Nitrobenzyl alcohol (3NBA) as the matrix. NMR spectra 
were measured using Bruker DPX 300 [300 MHz (1H) and 75 MHz (13C)] instruments 
using CDCl3 as a solvent (unless otherwise specified). The solvent peaks acted as the 
internal standards. For CDCl3, δH 7.26, δC 77.0; for acetone-d6, δH 2.05, δC 30.5. 
Multiplicities were determined using the DEPT pulse sequence. Coupling constants (J) 
were measured in Hertz (Hz).  
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Scleroderma sp. 
Plant material and Extraction 
Scleroderma sp. was collected in collected in Malaysia. The fungi was homogenized with 
methanol (MeOH) and kept for about a weeks in the dark at room temperature. Filtration 
and removal of solvent under vacuum afforded a red solid (ca. 12 g). 
 
Isolation 
The crude extract was chromatographed on a silica gel column eluted with a solvent 
gradient (hexane-acetone-methanol) to afford 6 fractions. 
 
Fraction 1 
The TLC and 1H NMR results of this fraction (1 g) showed that it did not contain 
interesting metabolites and therefore were not investigated further. 
 
Fraction 2 
The fraction (ca. 8 g) was chromatographed silica gel column (20 % acetone-hexane) to 
afford 6 subfractions.  
 
Subfraction 2.1 
The TLC and 1H NMR results of this subfraction (0.5 g) showed that it did not contain 




Subfraction 2.2 (2 g) 
One-sixth of this subfraction (350 mg) was chromatographed on silica gel column (30 % 
acetone-hexane) to get two fractions. The first fraction (100 mg) contains no interesting 
metabolites based on TLC and 1H NMR results. The second fraction was further 
chromatographed on silica gel column (70 % CH2Cl2) to get two compounds, methyl per-
O-methyl-4E-atromentate (57) (20 mg) and methyl per-O-methyl-4Z-atromentate (58) 
(60 mg).  
 
Subfraction 2.3  
The TLC and 1H NMR results of this subfraction (1 g) showed that it did not contain 
interesting metabolites and therefore were not investigated further. 
 
Subfraction 2.4 (1 g) 
One fifth of this fraction (200 mg) was chromatographed on silica gel column (20 % 
EtOAc-hexane) to afford three fractions. The first two fractions were mixture of the 
compounds contained in subfraction 2.2 and thus were not further studied. The third 
fraction (100 mg) was chromatographed on DIOL column (20 % EtOAc-hexane) to 
afford the compound, (22R,23E)-22-Acetoxylanosta-8,23-diene-3α,25-diol (70) (15 mg).   
 
Fraction 2.5 (1.5 g) 
One-third of this subfraction (500 mg) was chromatographed on silica gel column (40 % 
CH2Cl2-hexane) to give two fractions. The second fraction (100 mg) contains no 
interesting metabolites based on 1H NMR and TLC results. The first fraction (350 mg) 
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was further chromatographed on reversed phase column (C18, 40 % MeOH-H2O) to 
afford the compound, methyl 4,4’-di-O-melthylatromentate (56) (135 mg)  
 
Subfraction 2.6 (1 g) 
One-fifth of this subfraction (200 mg) was chromatographed on DIOL column eluted 
with a solvent gradient (10 % CH2Cl2/hexane to 80 % CH2Cl2/hexane) to give 3 fractions. 
The first two fractions were mixture of the compounds contained in subfractions and thus 
were not further studied. The third fraction is pure and it is methyl 3’,5’-dichloro-4,4’-di-
O-methylatromentate (66) (20 mg) 
 
Fraction 3—5  
These fractions (1.5 g) were mixture of the compounds contained in fraction 2  and thus 
were not further studied. 
 
Fraction 6 
The sixth fraction (0.5 g) was a methanol fraction and comprised mainly of highly polar 
compound such as sugar. Thus, it was not further investigated.  
 
Methyl-4,4’-di-O-methylatromentate (56) Orange-red solid; UV (methanol) λmax nm: 
230, 260, 305 and 385; FI-IR νmax (CHCl3) cm
-1: 3547, 1770, 1680, 1600, 1513, 1456, 
1250 and 1068; 1H NMR (300 MHz, CDCl3): δ 13.56 (1H, br s, 3-OH), 8.13 (2H, d, J = 
9.06 Hz, H-2’ and H-6’), 7.20 (2H, d, J = 8.70 Hz, H-8 and H-12), 6.96 (2H, d, J = 9.06 
Hz, H-3’and H-5’), 6.94 (2H, d, J = 8.70 Hz, H-9 and H-11), 3.89 (3H, s, 6-OCH3) and 
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3.82 (6H, s, 4’-OCH3 and 10-OCH3); 
13C NMR (75 MHz, CDCl3): δC 171.79 (C-6), 
166.13 (C-1), 159.60 (C-4’), 159.40 (C-10), 158.60 (C-3), 154.58 (C-4), 131.37 (2×, C-8 
and C-12), 129.23 (2×, C-2’ and C-6’), 124.96 (C-7), 121.67 (C-1’), 115.00 (C-5), 113.82 
(2×, C-3’ and C-5’), 113.47 (2×, C-9 and C-11), 104.97 (C-2), 55.19 (2x, 4’-OCH3 and 
10-OCH3) and 54.36 (6-OCH3). 
 
Methyl per-O-methyl-4E-atromentate (57) Yellow solid; UV (methanol) λmax nm: 235, 
363; FI-IR νmax (CHCl3) cm
-1: 1768, 1732, 1600, 1510, 1461, 1255 and 1050; 1H NMR 
(300 MHz, CDCl3): δ 7.64 (2H, d, J = 8.90 Hz, H-2’ and H-6’), 7.48 (2H, d, J = 8.70 Hz, 
H-8 and H-12), 6.97 (2H, d, J = 8.70 Hz, H-9 and H-11),  6.93 (2H, d, J = 8.90 Hz, H-
3’and H-5’), 3.89 (3H, s, 3-OCH3) and 3.82 (6H, s, 4’-OCH3 and 10-OCH3), 3.76 (3H, s, 
6-OCH3); 
13C NMR (75 MHz, CDCl3): δC 167.99 (C-6), 167.27 (C-1), 162.05 (C-3), 
160.32 (C-10), 159.97 (C-4’), 140.17 (C-4), 130.93 (2×, C-8 and C-12), 130.68 (2×, C-2’ 
and C-6’), 123.51 (C-7), 120.51 (C-1’), 115.81 (C-5), 114.23 (2×, C-3’ and C-5’), 113.93 
(2×, C-9 and C-11), 108.07 (C-2), 60.85 (3-OCH3), 55.35 (2×, 4’-OCH3 and 10-OCH3) 
and 52.63 (6-OCH3). 
 
Methyl per-O-methyl-4Z-atromentate (58) Yellow oil; UV (methanol) λmax nm: 235, 
360; FI-IR νmax (CHCl3) cm
-1: 1772, 1728, 1601, 1572, 1512, 1462, 1250 and 1035; 1H 
NMR (300 MHz, CDCl3): δ 7.57 (2H, d, J = 8.90 Hz, H-2’ and H-6’), 7.34 (2H, d, J = 
8.70 Hz, H-8 and H-12), 6.95 (2H, d, J = 8.90 Hz, H-3’and H-5’), 6.90 (2H, d, J = 8.70 
Hz, H-9 and H-11),  3.85 (3H, s, 6-OCH3) and 3.84 (6H, s, 4’-OCH3 and 10-OCH3), 3.34 
(3H, s, 3-OCH3); 
13C NMR (75 MHz, CDCl3): δC 167.12 (C-6), 166.32 (C-1), 162.20 (C-
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3), 160.22 (C-10), 160.11 (C-4’), 144.03 (C-4), 131.31 (2×, C-8 and C-12), 130.90 (2×, 
C-2’ and C-6’), 123.74 (C-7), 120.71 (C-1’), 116.81 (C-5), 114.01 (2×, C-3’ and C-5’), 
113.43 (2×, C-9 and C-11), 60.31 (3-OCH3), 55.33 (2×, 4’-OCH3 and 10-OCH3) and 
52.81 (6-OCH3). 
 
Methyl 3’,5’-dichloro-4,4’-di-O-methylatromentate (66) Yellow solid; UV (methanol) 
λmax nm: 276, 395; FI-IR νmax (CHCl3) cm
-1: 3530, 1780, 1680, 1600, 1550, 1512, 1249 
and 1072; EI-MS m/z (rel. int.): 418/420/422 [M-CH3OH]
+ (100/65/11), 362/364 (35/20), 





35Cl2O6 requires m/z 
421.9948/419.9981/418.0011); 1H NMR (300 MHz, CDCl3): δ 13.42 (1H, br s, 3-OH), 
8.12 (2H, d, J = 9.11 Hz, H-2’ and H-6’), 7.19 (2H, s, H-9 and H-11), 6.97 (2H, d, J = 
9.11 Hz, H-3’and H-5’),  3.97(3H, s, 10-OCH3) and 3.90 (3H, s, 6-OCH3), 3.85 (3H, s, 
4’-OCH3); 
13C NMR (75 MHz, CDCl3): δC 170.74 (C-6), 165.68 (C-1), 159.85 (C-3 or C-
4 or C-10 or C-4’), 158.01 (C-3 or C-4 or C-10 or C-4’), 155.84 (C-3 or C-4 or C-10 or 
C-4’), 152.34 (C-3 or C-4 or C-10 or C-4’), 130.45 (2x, C-8 and C-12),  129.51 (2x, C-2’ 
and C-6’), 129.21 (C-7), 129.13 (2x, C-9 and C-11), 121.30 (C-1’), 114.13 (2x, C-3’ and 
C-5’), 112.15 (C-5), 105.82 (C-2), 60.72 (10-OCH3), 55.28 (4’-OCH3) and 54.62 (6-
OCH3). 
 
(22R,23E)-22-Acetoxylanosta-8,23-diene-3α,25-diol (70) (15 mg). White sold; UV 
(methanol) λmax nm:265, 280 and 295 nm; FT-IR νmax (CHCl3) cm
-1: 3378, 1736, 1250 
and 1035; EI-MS m/z (rel. int.): 500 [M]+ (3), 482 [M-H2O]
+ (8), 440 [M-AcOH]+ (7), 
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425 [M-AcOH-CH3]
+ (19), 407 [M-AcOH-CH3-H2O]
+ (43), 389 [M-AcOH-CH3-2H2O]
+ 
(21), 325 [M-C8H13O3-H2O]
+ (10), and 134 (100); HREI-MS: m/z 500.3864 (C32H52O4 
requires m/z 500.3852); 1H NMR (300 MHz, CDCl3): δ 5.86 (1H, d, J = 15.60 Hz, H-24), 
5.62 (1H, dd, J = 7.75 and 15.60 Hz, H-23), 5.30 (1H, dd, J = 3.45 and 7.75 Hz, H-22), 
3.42 (1H, br s, H-3β), 2.05 (3H, s, CH3CO), 1.32 (6H, s, H3-26 and H3-27), 0.98 (3H, s, 
H3-19), 0.97 (3H, s, H3-28), 0.94 (3H, d, J = 6.60 Hz, H3-21), 0.87 (3H, s, H3-30), 0.83 
(3H, s, H3-29),  and 0.70 (3H, s, H3-18); 
13C NMR (75 MHz, CDCl3): δC 170.12, 142.09 
(C-24), 134.87 (C-8), 133.86 (C-9), 120.89 (C-23), 76.75 (C-22), 76.02 (C-3), 70.69 (C-
25), 49.54 (C-14), 47.11 (C-17), 44.75 (C-13),  44.21 (C-20), 40.46 (C-5), 37.60 (C-4), 
36.94 (C-10), 29.82 (C-12), 30.95 (C-15), 30.86 (C-16), 30.10 (C-26), 29.94 (C-27), 
28.00 (C-28), 27.17 (C-2), 26.08 (C-7), 25.74 (C-1), 24.13 (C-30), 22.19 (C-18), 21.49, 













Chapter 3 Chemistry of Leptoscyphus expansus (Lehm.) Grolle 
3.1 Introduction 
The bryophytes are taxonomically placed between the algae and the pteridophytes and 
25000 species are now known world-wide. They are divided into three classes, Musci 
(mosses, 14000 species), Hepaticae (liverworts, 6000 species) and Anthocerotae 
(hornworts, 300 species).  Among the bryophytes, the chemical constituents of the 
Hepaticae have been studied in more detail. Mues (1985) estimated that only 6 % of all 
liverwort species have been investigated chemically [83]. Markham estimated that the 
figure for mosses is probably less than 2 % [84]. Hence the chemistry of a liverwort 
species was studied here. 
 
In this study, the chemical constituents of the liverwort, Leptoscyphus expansus (Lehm.) 
Grolle were investigated.  Leptoscyphus expansus (Lehm.) Grolle belong to the family 
Lophocoleaceae. The Lophocoleaceae are divided into five genera: Chiloscyphus, 
Clasmatocolea, heteroscyphus, Leptoscyphus and Lophocolea [85]. The genus 
Leptoscyphus Mitt. was treated on a worldwide basis by Grolle (1962) [86]. In that 
treatment species occurring in south temperate-subantarctic areas are L. aequatus (Hook. 
F. & Tayl.) Mitt., L. horizontalis (Hook.) Herz. and L. patagonicus (American 
temperate); L. expansus (Lehm.) Grolle occur in amphiatlantic temperate area; L. abditus 
(Sull.) Dugas in subantarctic area; and L. cuneifolius (Hook.) Mitt. is widespread around 
the globe. Leptoscyphus roughly includes 30 species that share a laterally compressed 
perianth with a more or less bilabiate mouth by reduction of the ventral lobe and a 
brownish gametophyte [87, 88].  
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The chemical constituents of Lophocoleaceae are not well studied. Only six species of 
Lophocoleaceae have been investigated chemically [85]. Among the genus Leptoscyphus 
Mitt., only Leptoscyphus liebmanianus have been investigated chemically [85]. 
Anastreptene (73), ent-spathulenol (74), β-barbatene (75), ent-bicyclogermacrene (76), 















   







3.2 Biosynthesis and bioactivity of flavones 
In this study, various flavones have been isolated. A total of five flavones with different 
methoxyl substitution have been isolated from L. expansus (Lehm.) Grolle. They are the 
main natural products isolated from this plant. A brief introduction of their biosynthetic 
pathway and their roles as bioactive agent is given below.  
 
The biosynthesis of flavones and other flavonoids are shown in Figure 5 and Figure 6. 
Flavones are products from phenylpropanoid pathway [89]. The general phenylpropanoid 
pathway is conserved in all plant species. In this core pathway, the amino acid 
phenylalanine (Phe) is converted into p-coumaroyl-CoA (79) in three enzymatic steps. In 
most species, chalcone synthase then condenses 79 with three molecules of malonyl-CoA 
to form an intermediate which will be shunted into the synthesis of two intermediates, 
4,2’,4’,6’-tetrahydroxychalcone (naringenin chalcone) (80) and 4,2’,4’-
trihydroxychalcone (isoliquiritigenin) (82). 80 is then converted to (2S)-5,7,4’-
trihydroxyflavanone (naringenin) (81) by chalcone isomerase (CHI) to form the primary 
C15 flavonoid skeleton. Recently, Shimada et al. (2003) reported that two types of CHIs 
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coexist in the legume Lotus japonicus. The type I CHIs are ubiquitous in the plant 
kingdom and convert naringenin chalcone (80) to naringenin (81). In contrast, the type II 
CHIs convert 82 into (2S)-7,4’-dihydroxyflavanone (liquiritigenin) (83) [90] (see Figure 
5). 81 and 83 are the precursors of many flavonoid and isoflavonoid compounds. 81 and 
83 can be converted by flavanone 3β-hydroxylase (F3H) to the corresponding flavonols 
quercetin (88) and kaempferol (89), by addition of a hydroxyl group at the C3 position. 
For flavone biosynthesis, flavone synthases (FNS) convert 81 and 83 into the 
corresponding flavone apigenin (85) and a dihydroxyflavone. Flavonoid 3’-hydroxylase 
and flavonoid 3’,5’-hydroxylase may also modify 81 with additional B-ring 
hydroxylations. 85 can be further modified by methylation, hydration, as well as 
dehydration to yield the corresponding flavones. In species that synthesize isoflavones, 
the enzyme isoflavone synthase (IFS) acts as the key metabolic entry point for the 
formation of all isoflavonoid compounds. IFS mediates the intramolecular aryl migration 
of both 81 and 83 to form the corresponding 2-hydroxyisoflavones, daidzein and 



















































81, R = OH







88, R = OH






dihydroxyflavone, R = H





R = H, daidzein (DAI)






Figure 6 Biosynthesis of corresponding flavonol, flavone and 2-hydroxyisoflavone from 
81 and 83. 
 
 
Flavones have been used as anti-oxidant. Both mammalian and plant peroxidases have 
been reported to produce aromatic oxyl radicals from several aromatic substrates and 
reactive oxygen species as part of a defense mechanism against pathogens [92].These 
organic and inorganic free radicals may also participate in plant physiological processes, 
such as lignification, cell wall biosynthesis, auxin catabolism, and wound healing [93]. 
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However, such reactive species can also contribute to progressive human tissue damage 
in chronic inflammatory diseases, as atherosclerosis, asthma, and rheumatoid arthritis [94]. 
Phenolic compound such as flavones have been used as one of the therapeutic strategies 
against these inflammatory diseases. 
 
Bors et al. [96] suggested that three structural features are important determinants of the 
free radical-scavenger potential of flavonoids: (a) the O-dihydroxy (catechol) system in 
the B-ring; (b) the 2,3-double bond conjugated with a 4-oxo function; and (c) the 
presence of 3- and 5-OH groups. Hence, the inhibitory effect of some of the flavones 
against Horseradish peroxidase (HRP) decreases from myricetin (87), quercetin (88), 
kaempferol (89) and galangin (90) [97]. HRP is a well-known and highly investigated 
member of the peroxidase. The HRP-catalyzed oxidation of luminol in the presence of 













 87                R1 = R2 = R3 = OH 
88           R1 = R2 = OH, R3 = H 
89           R1 = R3 = H, R2 = OH 




The free radical scavenger activity of phenolic compounds has been reported to mediate 
the inhibition of prostaglandin synthesis by cyclooxygenase, since this enzyme catalyzes 
the controlled peroxidation of arachidonic acid. Therefore, inhibition of cyclooxygenase 
peroxidative activity by phenolic compounds seems to be an important mechanism 
underlying their anti-inflammatory effect [95]. 
 
Some of the flavones such as kaempferol (89) and apigenin (85) are found to be 
possessing antimicrobial activity [98,99]. Phenolic compounds such as flavones are 
generally have significant antimicrobial activity and it is assumed that their function in 
tissues where they accumulate might be to provide chemical barriers to invading 
microorganisms. It has been postulated that the methylated, lipophilic flavonoids are 
especially suitable as protection against microorganisms because of the ease with which 
they penetrate bacterial cells [100].  
 
The flavone velutin (91) exhibits antitumour activity against KB cell lines by inhibition 
of DNA topoisomerase I [76]. DNA toposiomerases regularize the topological states of 
DNA during cellular events such as replication, transcription, and recombination, by 
transient cleavage of single or double DNA strands, by swiveling, and by relegation of 
initial bonds. It was suggested that a substance that can stabilize DNA topoisomerase 














3.3 Results and Discussion 
The chemistry of the liverwort in the genus Leptoscyphus is not well studied. Only the 
chemistry of Leptoscyphus liebmanianus has been reported previously. This is the first 
chemical investigation of Leptoscyphus expansus (Lehm.) Grolle in the hope to find new 
chemical constituents.  
  
The CH2Cl2 extract of Leptoscyphus expansus (Lehm.) Grolle afforded five known 
flavones, 5-hydroxyl-7-methoxyflavone (92), 5-hydroxy-7,4’-dimethoxyflavone (95), 
5,7-dimethoxyflavone (97), 5-hydroxy-6, 7-dimethoxyflavone (98) and 5, 6, 7-
trimethoxyflavone (Baicalein trimethyl ether) (102); a known chromene, methyl 5, 7-
dihydroxy-2, 2-dimethyl-2H-chromene-6-carboxylate (103); and a new bibenzyl, 2, 2-
dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) chromene (108) 
 
The identifications of the compounds were done by comparing the 1H, 13C, UV and IR 
spectral data with those of the authentic samples. HMBC and HMQC were done to 
confirm the identity of the compounds. Many of the flavones isolated from this liverwort 
are bioactive against various diseases. Hence the plant has high medicinal value. 
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5-hydroxyl-7-methoxyflavone (92) 
Compound 92 was obtained as a yellow solid. EI-MS of 92 showed a molecular ion [M]+ 
at m/z 268.1, consistent with the molecular formula C16H12O4, which was confirmed by 
HREI-MS (found [M]+ at m/z 268.0730, requires 268.0732). 1H and 13C NMR spectra of 
92 showed that it is a flavone derivative, which is characterized by olefinic C-2 and C-3 
resonances at 163.98 and 105.84 ppm, and a chelated keto C-4 at 182.48 ppm [61]. This 
was further verified by UV absorption bands at 269 and 306 nm. The UV spectrum of a 
flavone typically consists of two absorption maxima in the ranges of 250-280 nm (band 













The IR spectrum indicated the presence of an α,β-unsaturated carbonyl group (1668 cm-
1). The presence of hydroxyl groups were confirmed by the infrared absorption bands at 
3408 cm-1 and by the 1H NMR signal of a far-down field singlet at δH 12.71 (1H, br s, 5-
OH). This signal showed the presence of a hydroxyl group which is hydrogen-bonded to 
carbonyl group. Positive colouration of alcoholic ferric chloride test indicating that the 
hydroxyl group is phenolic. The 1H NMR spectrum of 92 (see Table 9) also shows the 
singlet signal of an olefinic proton at δH 6.66 (1H, s, H-3) indicating the presence of a 
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trisubstituted olefin group; as well as the signals of two meta coupled protons at δH 6.36 
(1H, d, J = 2.07 Hz, H-6) and δH 6.49 (1H, d, J = 2.07 Hz, H-8). The presence of a mono-
substituted benzene-ring was shown by the infrared absorption bands at 762 and 680 cm-1 
and by the A2B3 signals of the 
1H NMR spectrum at δH 7.88 (2H, m, H-2’ and H-6’) and 
7.53 (3H, m, H-3’, H-4’ and H-5’) [64]. .  The separation of aromatic signals into two 
groups (ortho protons at lower field and meta/para protons at upper field) indicating that 
the benzene ring is attached to an electron-withdrawing group or in this case a carbon-
carbon double bond (C-2, C-3 olefin group) [61]. Furthermore, 1H NMR spectrum exhibit 
an upfield signal at δH 3.88 (3H, s, 7-OCH3) suggesting the presence of a methoxyl 
group.  
 
The 13C NMR spectrum of 92 (see Table 9) showed signals for 16 carbons, including one 
chelated carbonyl group [δC 182.48 (C-4)], four oxygenated olefinic carbons [δC 157.78 
(C-9), 162.17 (C-5), 163.98 (C-2), and 165.60 (C-7)], eight olefinic methine [δC 92.66 
(C-8), 98.19 (C-6), 105.85 (C-3), 126.27 (C2’ and C-6’), 129.06 (C-3’ and C-5’) and 
131.81 (C-4’)], two olefinic quaternary carbon [δC 105.69 (C-10) and 131.30 (C-1’)], and 
a methoxyl group [δC 55.79 (7-OCH3)]. This compound therefore possess eleven unit of 
unsaturation which can be accounted for by two benzene rings, one carbonyl group and 
one C—C double bond. The carbonyl resonance (C-4) exhibits dependence upon the 
absence or presence of substituent at C-5 position [61]. The presence of C-5 hydroxyl 
causes ca. 4.5 ppm downfield shift of the C-4 resonance hence resulting C-4 resonance at 
δC 182.48 as compared to C-5 unsubstituted flavone (93) (see Table 8 and Table 9) 
[61]. 
The difference is due to an intramolecular hydrogen bond interaction between keto group 
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(C-4) and C-5 (peri) hydroxyl (Figure 7). The presence of C-5 hydroxyl also causes a ca. 
1.5 ppm upfield shift of C-3 to δC 105.84 as compared to the C-3 chemical shift in C-5 







Figure 7 Intramolecular hydrogen bond of 92 
 
 
The methoxyl group appears at δC 55.79 indicating that this methoxyl group bears at least 
one free ortho position [60]. Thus, there are three possible positions in which the methoxyl 
group can attach to (C-6, C-7 and C-8). This methoxyl group was not attached to C-6 
since there is no intense quinoid cation (M-15, m/z 253) in the mass spectrum. The 
presence of an intense quinoid cation [M-CH3]
+ is characteristic of flavones with the C6-
OCH3 group 
[110]. The molecular ion normally appears as a base peak in the mass 
spectrum of a flavone and must be an even mass number due to the presence of only 
oxygen, carbon and hydrogen atoms [61]. The fact that there are two meta coupled protons 
at δH 6.36 [1H, d, J = 2.07 Hz] and δH 6.49 [1H, d, J = 2.07 Hz], indicating that the 
methoxyl group is positioned at C-7. This is further verified by HMBC (see Figure 9 and 
Table 9), in which the methoxyl proton showed correlation to C-7. The presence of 
electron donating group at C-5 (hydroxyl group) and C-7 (methoxyl group) causes an 
upfield shift of C-6 (δC 98.19) and C-8 (δC 92.66) as compared to those of unsubstituted 
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flavone (93) (see Table 8 and Table 9). The structure of 92 was further confirmed by 
HMBC (Table 9 and Figure 9). The 1H, 13C, IR and UV spectral data of 92 are identical 
to those of 5-hydroxy-7-methoxyflavone [61,67,72]. 92 was previously isolated from the 
black rhizomes of Boesenbergia pandurata, which is used in folk medicine in Thailand 
for the treatment of colic disorders [68] and a Thai herb and its rhizomes Kampferia 
parviflora [72] and Cyathostemma argenteum [78]. 
 
 















Figure 8 The structure and 
numbering of flavone (93) 



















































Table 9 1H (300 MHz), 13C (75 MHz)  NMR and HMBC (125 MHz) data for 5-hydroxy-
7-methoxyflavone (92) in CHCl3. (J in Hz in parentheses) 























6.36 d (2.07) 
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Figure 9 HMBC correlations of 92 
 
The bioactivities of 92 have been studied elsewhere. Studies showed that 92 induces the 
elimination of many drugs and other xenobiotic, such as carcinogen and phytochemical 
from our body by enhancing the expression of the enzyme UDP-glucuronosyltransferase 
(UGT1A1) [71]. Thus, 92 shows anti-cancer properties. In the liver, elevated expression of 
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UGT1A1 could facilitate the glucuronidation of bilirubin, thereby normalizing the 
circulating levels of this endogenous toxin [69]. In the colon, elevated expression of 
UGT1A1 could increase the glucuronidation of the colon carcinogen N-hydroxy-2-
amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine, thereby protecting this tissue from 
carcinogenesis [70]. Walle et al. (2002) found that C-5 and C-7 hydroxyl are essential for 
the induction of UGT1A1 expression. If one of the positions is unsubstituted or 
substituted with other groups, it will cause a reduction in the degree of induction of 
UGT1A1. They showed that chrysin (94) (5,7-dihydroxyflavone) exhibit a higher degree 






















Compound 95 was obtained as a yellow solid. EI-MS of 95 showed the molecular ion 
[M]+ at m/z 298.0, consistent with the molecular formula C17H14O5, which was further 
confirmed by HREI-MS m/z 298.0841 (C17H14O5 requires m/z 298.0837). The molecular 
ion [M]+ of 95 is 30 mass units more than that of 92, indicating the presence of an 
additional methoxyl group. The UV spectrum in methanol showed absorption maxima at 















The IR spectrum indicated the presence of an α, β-unsaturated carbonyl group (1668 cm-
1) and a benzene ring (1600, 1587 and 1445 cm-1). The IR spectrum of 95 did not show 
mono-substituted benzene ring as in 92. The 1H NMR spectrum (see Table 10) showed 
the presence of two meta  coupled aryl-protons [δH 6.37 (1H, d, J = 2.07 Hz, H-6) and 
6.49 (1H, d, J = 2.07 Hz, H-8)], an olefinic proton [δH 6.58 (1H, s, H-3)], an AA’BB’ 
coupling system [δH 7.02 (2H, d, J = 7.5 Hz, H-3’ and H-5’) and 7.85 (2H, d, J = 7.5 Hz, 
H-2’ and H-6’)] indicating a para-substituted benzene ring, and two methoxyl groups [δH 
3.88 (3H, s, 7- or 4’-OCH3) and 3.90 (3H, s, 7- or 4’-OCH3)]. The 
13C NMR spectrum 
(see Table 10) showed signals of a chelated carbonyl [δC 182.47 (C-4)], five oxygenated 
olefinic quaternary carbons [δC 157.61 (C-9), 162.50 (C-4’), 162.13 (C-5), 163.92 (C-2) 
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and 165.40 (C-7)], seven olefinic methine groups [δC 92.63 (C-8), 98.04 (C-6), 104.21 
(C-3), 114.50 (C-3’ and C-5’), 128.05 (C-2’ and C-6’)], two olefinic quaternary carbons 
[δC 105.50 (C-10) and 123.38 (C-1’)] and two methoxyl groups [δC55.53 (-OCH3) 55.79 
(-OCH3) ]. 95 contained seventeen carbons with eleven units of unsaturation, which can 
be accounted for by two benzene rings, a keto group and one C—C double bond. 
 
The 1H and 13C NMR of this compound are similar to those of compound 92 and 93, 
indicating that 95 must be a flavone derivative. The only difference between 95 and 92 is 
the presence of a para-substituted benzene ring and an additional methoxyl group in 95. 
Apparently, the mono-substituted benzene ring in 92 has been substituted by the para-
substituted benzene ring in 95. The appearance of C-10 at δC 105.51 suggests that there is 
an electron donating group ortho to it (C-5). At first glance, it was thought that the 
electron-donating group was methoxyl since there was no other electron-donating group 
other than methoxyl based on 1H NMR spectrum. However, the appearance of C-4 
carbonyl carbon at δC 182.47 indicated that there is a C-5 hydroxyl group. As mention 
earlier, the chemical shift of C-4 carbonyl carbon is affected by C-5 hydroxyl group. It 
forms intramolecular hydrogen bond with C-4 carbonyl oxygen. In addition to that, C-5 
hydroxyl also causes an upfield shift of C-3 to δC 104.21. Although the hydroxyl signal 
was not shown in the 1H NMR spectrum, the presence of it was confirmed by the infrared 
absorption bands at 3405 cm-1. This was further verified by positive colouration of the 
compound with alcoholic ferric chloride test. The fact that there are two meta coupled 
protons [δH 6.37 (1H, d, J = 2.07 Hz, H-6) and 6.49 (1H, d, J = 2.07 Hz, H-8)] suggest 
that one of the methoxyl groups is attaching to C-7. The presence of electron donating 
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groups at C-5 (hydroxyl group) and C-7 (methoxyl group) causes an upfield shift of C-6 
(δC 98.04) and C-8 (δC 92.63). This is consistent with those of compound 92 (see Table 
9).The second methoxyl group must be attached to C-4’ of ring B. The presence of 
methoxyl group causes a downfield shift of C-4’ (δC 162.50) and upfield shift of C-3’ and 
C-5’ (δC 114.50). The EI-MS fragment pattern, 
1H, 13C NMR, UV and IR spectral data of 
95 were in good agreement with those of 5-hydroxy-7,4’-dimethoxyflavone [68,72,73,77]. 95 
has been isolated previously from Boesenbergia pandurata [68], Kaempferia parviflora 
[72], Baccharis rhomboidalis [77], Gonystylus bancanus [80] and Lethedon tannaensis [76].  
 
The bioactivity of 95 has been reported elsewhere [76, 81]. The plant L. tannaensis is used 
in New Caledonia as folk medicine, and as antibacterial agent [76]. Both Genkwanin (5,4’-
dihydroxy-7-methoxyflavone) (96) and 95 are isolated from the plant. Studies found that 
flavones required the presence of hydroxyl groups at C-5 and C-4’ for inhibition of DNA 
topoisomerase I [76], which later leading to cell death. This also explains the lower 
bioactivity of compound 95 against various bacterial diseases as compared to 96. 
However, Wang et al. (1992) found that the bioactivity of 95 can be enhanced by 
complexation with metal ion (Cu2+, Ni2+, Co2+, Zn2+, Fe2+, Cr3+, Cd2+ and Mn2+) through 
C-4 keto oxygen and C-5 hydroxyl oxygen. They found that Cu2+, Ni2+, Co2+, Zn2+, Cd2+ 
and Mn2+ form 1:2 (metal: ligand) complexes while Fe2+ and Cr3+ form 1: 3 complexes 
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M = Co, Cu, Ni  M = Cd, Zn, n = 1  M = Cr, Fe, n = 3 
    M = Mn, n = 1.5 
 










Table 10 1H (500 MHz) and 13C (125 MHz) NMR data for 5-hydroxy-7,4’-
dimethoxyflavone (95) in CHCl3. (J in Hz in parentheses) 
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* May be interchangeable within the same column. 
















Compound 97 was obtained as yellow solid. EI-MS of 97 showed molecular ion [M]+ at 
m/z 282.0, consistent with the molecular formula C17H14O4, which is confirmed by 
HREI-MS (found [M]+ m/z at 282.0882, requires 282.0888). The molecular ion [M]+ 
peak was also the base peak of the mass spectrum. The UV spectrum of 97 in methanol 
showed absorption maxima at 264 and 307 nm, which is consistent with the absorption 
maxima of a flavone [62]. The IR spectrum exhibit absorption bands at 1643, 1610, 1600, 
1460, 1213 and 1117, 790 and 681 cm-1, indicating the presence of chelated carbonyl 














The 1H and 13C spectra of 97 (see Table 11) showed the signals of two meta coupled 
protons [δH 6.31 (1H, d, J = 2.0 Hz, H-6), and 6.52 (1H, d, J= 2.0 Hz, H-8); δC 96.09 (C-
6) and 92.73 (C-8)], an olefinic proton [δH 6.63 (1H, s, H-3); δC 108.69 (C-3)], a mono-
substituted benzene ring [δH 7.81 (ortho-protons, 2H, m, H-2’ and H-6’) and 7.45 (meta- 
and para-protons, 3H, m, H-3’, H-5’ and H-4’; δC 125.82 (ortho, C-2’ and C-6’), 128.79 
(meta, C-3’ and C-5’), and 131.12 (para, C-4’)], and two aryl-methoxyl group [δH 3.86 
(3H, s, -OCH3) and 3.89 (3H, s, -OCH3); δC 55.64 (-OCH3) and 56.19 (-OCH3)]. 
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Furthermore, the 13C spectrum also showed the presence of six olefinic quaternary 
carbons, among which four are oxygenated [δC 108.67 (C-10), 131.24 (C-1’), 159.75 (C-
9), 160.71 (C-5), 161.0 (C-2) and 164.06 (C-7)]. Therefore the compound has eleven 
units of unsaturation which can be accounted for by two benzene rings, a keto group and 
one C—C double bond. The 1H and 13C NMR spectra of 97 are similar to those of 92 and 
93. Thus, 97 is postulated to be a flavone derivative. However, 97 differed from 92 in that 
it lacks a hydroxyl group but contain an additional methoxyl group. The absence of 
hydroxyl group in the compound is further verified by the absence of hydroxyl absorption 
bands in the IR spectrum. The chemical shift of C-4 resonance  appeared at δC 177.66, 
due to the absence of C-5 hydroxyl group as compared to that in 92 (δC 182.48). This is 
due to the fact that there is no intramolecular hydrogen bonding between the C-4 
carbonyl oxygen and the C-5 hydroxyl group. The absence of C-5 hydroxyl also causes a 
ca. 2.8 ppm downfield shift of C-3 (δC 108.69) as compared to that in 92 (δC 105.85). The 
two methoxyl groups appear at δC 55.64 and δC 56.19 indicating that both groups bear at 
least one free ortho position. The C-5 hydroxyl group was substituted by a methoxyl 
group. This caused an upfield shift of C-10 to δC 108.67 as compared to that in 93 (δC 
124.0). The fact that there are two meta coupled protons [δH 6.31 (1H, d, J = 2.0 Hz, H-
6), and 6.52 (1H, d, J= 2.0 Hz, H-8); δC 96.09 (C-6) and 92.73 (C-8)] suggest that the 
second methoxyl group must be attached to C-7. The presence of electron donating 
groups (methoxyl groups) at C-5 and C-7 causes an upfield shift of C-6 (δC 96.09) and C-
8 (δC 92.73) as compared to those in 93 [C-6 (δC 124.9) and C-8 (δC 117.9), see Table 8]. 
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These data shows that compound 97 is 5,7-dimethoxyflavone. The mass fragments of 97 
and its UV, IR and 1H NMR data were identical to those reported for 5,7-
dimethoxyflavone [68, 72, 73, 74]. 97 has been previously isolated from a black rhizome of 
Boesenbergia pandurata 
[68], the Australian traditional medicinal plant Leptospermum 
scoparium [74], Macaranga triloba [73] and Kaempferia parviflora [72]. 
 
Wen et al. (2005) showed that 5,7-dimethoxyflavone (97) possesses chemopreventive 
properties  against liver cancer, hepatocellular carcinoma (HCC) [75]. They concluded in 
their study that the compound has potent inhibitory effect against the disease. HCC is an 
environmentally related cancer, with the highest mortality rate in developing countries. 
Polycyclic aromatic hydrocarbons (PAHs) present in the cigarette smoke are the main 
reason for the disease.  Benzol[a]pyrene (BaP), the main PAH present in cigarette smoke, 
is metabolized by human cytochrome (CYP) 1A1 and epoxide hydrolase to carcinogenic 
BaP 7,8-diol-9,10-epoxides, which covalently binds to cellular DNA to start the 
carcinogenic process. 5,7-Dimethoxyflavone acts by decreasing the expression as well as 
direct inhibition of the cytochrome CYP1A1. Decreased level of CYP1A1 abolished the 









Table 11 1H (300 MHz) and 13C (75 MHz) NMR data for 5,7,-dimethoxyflavone (97) in 
CHCl3. (J in Hz in parentheses) 
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5-Hydroxy-6, 7-dimethoxyflavone (98) 
Compound 98 was obtained as a yellow solid. EI-MS of 98 showed molecular ion [M]+ at 
m/z 298.0, consistent with the molecular formula C17H14O5, which is confirmed by HREI-
MS (found [M]+ at m/z 298.0837 , requires 298.0841). It has the same molecular formula 
as compound 95. They are thus structural isomers. The UV spectrum in methanol showed 
absorption maxima at 280 and 310 nm, which is also consistent with that of a flavone [62]. 
The IR spectrum showed the presence of a hydroxyl group [3500 cm-1, OH], α, β-
unsaturated carbonyl group [1675 cm-1, C=O], a benzene ring [1600 and 14601 cm-1] and 















The 1H NMR spectrum (see Table 12) showed that the compound contained a mono-
substituted benzene ring [δH 7.89 (ortho-protons, 2H, m, H-2’ and H-6’) and 7.53 (meta- 
and para-protons, 3H, m, H-3’, H-5’ and H-4’], two olefinic protons [δH 6.68 (1H, s, H-3) 
and 6.57 (1H, s, H-8)], two methoxyl groups [δH 3.93 (3H, s, 6- or 7-OCH3) and 3.97 
(3H, s, 6- or 7-OCH3)] and a sharp singlet hydroxyl group [δH 12.67 (1H, s)]. As the two 
olefinic protons [δH 6.68 (1H, s, H-3) and 6.57 (1H, s, H-8)] showed no coupling it was 
suggested that one occurred at C-3 and the other in the A-ring leading to the conclusion 
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that the compound was a 5-hydroxy flavone  substituted in the A-ring with two methoxyl 
groups.  
 
The 13C spectrum (see Table 12) showed signals of a chelated carbonyl group [δC 182.72 
(C-4)], five oxygenated olefinic quaternary carbons [δC 132.68 (C-6), 153.02 (C-5), 
153.32 (C-9), 158.90 (C-7), 163.96 (C-2)], seven olefinic methine carbons [δC 90.63 (C-
8), 105.61 (C-3), 126.24 (C2’ and C-6’), 129.08 (C-3’ and C-5’), and 131.83 (C-4’)], two 
olefinic quaternary carbons [δC 106.29 (C-10) and 131.29 (C-1’)] and two methoxyl [δC 
56.32 (-OCH3) and 60.85 (-OCH3). The data showed that this compound possesses 
seventeen carbons with eleven units of unsaturation, which can be accounted for by two 
benzene rings, one keto group and one C—C double bond. The appearance of C-4 keto 
carbon at δC 182.72 and C-3 at δC 105.61 indicate the presence of C-5 hydroxyl group as 
discussed previously.  
 
Since the B-ring is mono-substituted (based on 1H NMR), the two methoxyl groups 
should be attached to A-ring. The carbon chemical shifts of OMe substituents usually 
occur between 55.0 and 56.5 ppm (normal methoxyl) but in some cases they are observed 
further downfield between 59.5 and 63.0 ppm. This deshielding effect is seen only when 
the OMe is di-ortho substituted by two bulky substituents such as other OMe, or OH, or a 
ring junction. Dhanmi and Stothers have suggested that this is due to steric hindrance to 
resonance between oxygen atom of the OMe and the aromatic ring [60]. Hofer suggested 
that the normal OMe substituent on an aromatic system favours a conformation lying in 
the plane of the ring (coplanar aryl-O-bond) to permit maximum overlap between the 
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orbitals of the oxygen lone pair and the π-orbitals of the aromatic nucleus, leading to a 
delocalization of the non-bonding oxygen electrons and strengthening Ar-O bond. This 
results in increased electron density at the aryl ring carbons ortho and para to the 
methoxyl group [63]. In the out of plane conformation, which is expected for di-ortho 
substituted methoxyl, the conjugation of the nonbonding oxygen electrons with the bond 
of the ring is interrupted, hence resulting to the decreased electron density on methoxyl, 
ortho and para carbons [63]. It would follow therefore that where there is an ubsubstituted 
position adjacent to an OMe, the Me carbon will be shielded by the conjugated electrons 
whereas in other cases, when the oxygen is not fully conjugated, it will become relatively 
deshielded. 
 
One of the methoxyl groups is di-ortho substituted (δC 60.85) based on 
13C NMR 
spectrum. There are two possible structures for this type of substitution. That methoxyl is 
either flanked between the second methoxyl and a hydroxyl as in 5-hydroxy-6, 7-
dimethoxyflavone, or between the second methoxyl and a ring junction as in 5-hydroxy-
7, 8-dimethoxyflavone (see Figure 11). The structure of compound 98 was confirmed by 
comparing its 1H NMR spectrum with those of alnustin (5-hydroxy-3, 6, 7-
trimethoxyflavone) (100) and 5-hydroxy-3, 7, 8-trimethoxyflavone (101) (see Figure 12). 
The literature registers δH 6.54 for H-8 of alnustin 
[64] but δH 6.45 for H-6 for 5-hydroxy-
3, 7, 8-trimethoxyflavone [65]. So the value δH 6.57 must be placed at H-8 of compound 
98. Thus, 98 was named 5-hydroxy-6, 7-dimethoxyflavone. This was further verified by 
mass spectrometry. The position of the methoxyl group was confirmed to be C-6 by the 
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intense quinoid cation (99) (M-CH3, m/z 283, rel. int. 70 %) in the mass spectrum, which 












The mass fragments of 98 and its UV, IR and 1H NMR data were identical to those 
reported for 5-hydroxy-6,7-dimethoxyflavone [78,79]. This compound has been previously 
reported as chemical constituent from Popowia Cauliflora [79] and Cyathostemma 
















Figure 11 5-hydroxy-6,7-dimethoxy and 5-hydroxy-7,8-dimethoxy substitution pattern 





















100      101 
 
Figure 12 Alnustin and 5-hydroxy-3, 7, 8-trimethoxyflavone with their 1H resonance at 





Table 12 1H (500 MHz) and 13C (125 MHz) NMR data for 5-hydroxy-6,7-
dimethoxyflavone (98) in CHCl3. (J in Hz in parentheses) 





























































5, 6, 7-Trimethoxyflavone (Baicalein trimethyl ether) (102) 
Compound 102 was obtained as a yellow solid. EI-MS of 102 showed a molecular ion 
[M]+ at m/z 312.0, consistent with the molecular formula C18H16O5, which is confirmed 
by HREI-MS (found [M]+ at m/z 312.0998, requires 312.0993). The UV spectrum 
showed absorption maxima at 270 and 305 nm. The IR spectrum of compound 102 
showed the presence of unsaturated carbonyl group [1625 cm-1 (C=O)], benzene ring 
















The 1H NMR spectrum (see Table 13) showed that the compound contained a mono-
substituted benzene ring [δH 7.83 (ortho-protons, 2H, m, H-2’ and H-6’) and 7.45 (meta- 
and para-protons, 3H, m, H-3’, H-5’ and H-4’), two olefinic protons [δH 6.78 (1H, s, H-3) 
and 6.64 (1H, s, H-8)], and three methoxyl groups [δH 3.86 (3H, s) and 3.92 (3H, s) and 
3.93 (3H, s)]. As the two olefinic protons [δH 6.78 (1H, s) and 6.64 (1H, s)] showed no 
coupling it was assumed that one occurred at C-3 and the other in the A-ring leading to 
the conclusion that three methoxyl groups attached to the A-ring of the compound. This 
is further verified by 13C NMR spectrum. The 13C spectrum (see Table 13)  showed 
signals of a chelated carbonyl group [δC 177.42 (C-4)], five oxygenated olefinic 
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quaternary carbons [δC 140.22 (C-6), 152.25 (C-5), 154.43 (C-9), 157.80 (C-7), 161.23 
(C-2)], seven olefinic methine carbons [δC 96.16 (C-8), 107.94 (C-3), 125.84 (C2’ and C-
6’), 128.80 (C-3’ and C-5’), and 131.22 (C-4’)], two olefinic quaternary carbons [δC 
112.55 (C-10) and 131.50 (C-1’)] and three methoxyl [δC 56.16 (7-OCH3) and 61.34 (5- 
or 6-OCH3) and 62.01 (5- or 6-OCH3)]. 
 
The occurrence of two of the chemical shifts of methoxyl carbons at 61.34 and 62.01 
ppm, and one at 56.16 ppm, requires two of the methoxyl groups to be flanked by either 
other methoxyl or ring junctions, and only one to be ortho to a proton. Such a situation is 
only met by the 5, 6, 7-, or biogenetically unlikely 6, 7, 8-, substitution pattern (see 
Figure 13). The occurrence of C-10 at 112.55 ppm showed that there is an electron-
donating group ortho to C-10 (i.e C-5). Since there is no hydroxyl group (based on 1H 
NMR, IR spectrum as well as ferric chloride test), the only electron-donating group 
attaching to C-5 is methoxyl. Thus, the structure of 102 is confirmed as 5, 6, 7-
trimethoxyflavone. The mass fragments of 102 and its UV, IR and 1H NMR data were 
identical to those reported for 5, 6,7-trimethoxyflavone [117,118]. 102 has been previously 















Figure 13 5,6,7-trimethoxy and 6, 7,8-trimethoxy substitution pattern of A ring. 
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Table 13 1H (300 MHz) and 13C (75 MHz) NMR data for 5,6,7-trimethoxyflavone (102) 
in CHCl3. (J in Hz in parentheses) 























































* Signals with the same superscript within any column may be interchanged. 
 
 
The bioactivities of 102 have been reported elsewhere [82,107]. It exhibited relatively high 
inhibitory effects on herpes simplex virus type 1 (HSV-1), human cytomegalovirus 
(HCMV) and poliovirus [82]. The anti-HSV-1 action was not due to the inhibition of virus 
adsorption, entry and viral protein synthesis, but might involve, at least in part, a 
virucidal activity, which results in a suppression of viral binding to host cells at an early 
replication stage. 102 also showed synergic effect with the anti-viral drug acyclovir. 
Monotherapy with only acyclovir is often limited by the development of drug resistance. 
102 was shown to inhibit both enveloped viruses (HSV1 and HCMV) and unenveloped 
virus (poliovirus). Furthermore, acyclovir-sensitive and acyclovir-resistant strains of 
HSV-1 showed relatively high sensitivity to 102 [82]. 
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Studies also showed that 102 is bioactive against X-linked adrenoleukodystrophy (X-
ALD) [107].  X-ALD is an inherited disorder characterized by the progressive 
demyelination of the central nervous system and adrenal insufficiency.  The biochemical 
characterization of the disease is made based on the accumulation of pathognomonic 
amounts of saturated very long chain fatty acids (VLCFA, >C22) in body fluids and 
tissues, including brain white matter and adrenal glands. The disease may be due to the 
reduction of VLCFA β-oxidation activity which leads to the accumulation of VLCFA. It 
was found that 102 stimulated VLCFA β-oxidation. 102 is thought to activate 
mitochondrial β-oxidation, which in turn leads to the stimulation of peroxisomal VLCFA 
β-oxidation [48]. The methoxy residues of 102 are important for the activity of the 
compound. Recently, certain flavonoids have been reported to cross the blood-brain 













Methyl 5, 7-dihydroxy-2, 2-dimethyl-2H-chromene-6-carboxylate (103) 
Compound 103 was obtained as yellow oil. The EI-MS of compound 103 showed 
molecular ion [M]+ at m/z 250.0, consistent with the molecular formula C13H14O5, which 
is confirmed by HREI-MS (found 250.0840, requires 250.0837). The UV spectrum of 
103 in methanol showed absorption maxima at 262 and 333 nm. The IR spectrum of 103 
showed the presence of hydroxyl groups (3437 cm-1, OH), unsaturated carbonyl group 




















The 1H and 13C NMR of 103 (see Table 14) showed signals for two methyl groups [δH 
1.42 (H-12 and H-13); δC 28.29 (C-12 and C-13)], two coupled olefinic protons [δH 5.46 
(1H, d, J = 10.11 Hz, H-3) and 6.61 (1H, d, J = 10.11 Hz, H-4); δC 125.90 (C-3) and 
115.91 (C-4)], one uncoupled aromatic proton [δH 5.96 (s, H-8); δC 96.75 (C-8)], and a 
methoxyl [δH 4.03 (3H, s), δC 52.48 (-OCH3)]. The 
13C NMR spectrum also showed an 
oxygenated sp3 quaternary carbon [δC 77.74 (C-2)], in which the two methyl groups 
attached. This together with the two coupled olefinic protons comprised the heterocyclic 










Figure 14 Chromene moiety 
 
The 13C NMR spectrum in CDCl3 showed only four signals for the aromatic ring subunit: 
three aromatic carbons [δC 102.31 (C-10), 96.75 (C-8) and 93.51 (C-6)], and one 
oxygenated carbon [δC 160.60]. However, the signal at δC 160.60 actually comprised of 
three oxygenated carbon instead of one (based on the peak intensity). If this is the case, it 
revealed the phloroglucinol moiety of the compound (see Figure 15). The upfield 
chemical shift of the only aromatic proton at δH 5.96 (s, H-8) supported this conclusion. 
This is further verified by comparing the proposed structure with the molecular formula 








Figure 15 Phloroglucinol moiety 
 
The 3J HMBC correlations of H-4 (δH 6.61)/C-5 and C-9 (δC 160.60) and that of H-3 (δH 
5.46)/C-10 (δC 102.31) established the fusion of the chromene ring at C-9 and C-10 with 
an ether linkage at C-9. The singlet aromatic proton was attributed to H-8 according to 3J 
HMBC correlations with C-10 and C-6 (δC 93.51). The occurrence of C-6 at δC 93.51 
suggested that C-6 was flanked between two electron-donating groups. It was suggested 
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that one of the electron-donating groups is methoxyl since it is the only electron-donating 
group shown in 1H NMR. However, further examination of 13C NMR of 103 revealed 
that the methoxyl form part of the ester [δC 169.79, 52.48, δH 4.03]. A correlation 
between the methoxyl protons and a carbonyl carbon at δC 169.79 indicated the presence 
of the methyl ester functionality. The electron-donating groups were later confirmed to be 
hydroxyl groups by IR spectrum and the molecular formula of the compound based on 




























Table 14 1H (500 MHz) and 13C (125 MHz) NMR data for Methyl 5, 7-dihydroxy-2, 2-
dimethyl-2H-chromene-6-carboxylate (103) in CHCl3. (J in Hz in parentheses) 



















5.46 d, J = 10.11 Hz 




















































However, the occurrence and position of the hydroxyl groups remain uncertain. The 
postulated structure could not be proven by NOESY experiment since there is no signal 
for hydroxyl in 1H NMR. So, the two hydroxyl groups are methylated by means of 
iodomethane in the presence of potassium carbonate in acetone.  
 
The methylated product (104) was obtained as yellow oil. The EI-MS of 104 showed 
molecular ion [M]+ at m/z 278.1, consistent with the molecular formula C15H18O5, which 
is confirmed by HREI-MS (found [M]+ at 278.1144, requires 278.1149). The UV showed 
absorption maxima at 232 and 286 nm. The IR showed the presence of unsaturated 
carbonyl group (1645 cm-1, C=O) and benzene ring (1607 and 1446 cm-1). The lack of 
hydroxyl group in the IR spectrum showed that compound 104 was totally methylated. 
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The 1H NMR and 13C spectra of 104 (see Table 15) showed signals for two methyl 
groups [δH 1.42 (H-12 and H-13); δC 27.82 (C-12 and C-13)], two coupled olefinic 
protons [δH 5.51 {1H, d, J = 10.1 Hz, H-3) and 6.48 {1H, d, J = 10.1 Hz, H-4); δC 127.72 
(C-3) and 116.48 (C-4)], one uncoupled aromatic proton [δH 6.20 (H-8, s); δC 96.16] and 
three methoxyl groups [δH 3.78 (3H, s), 3.80 (3H, s) and 3.89 (3H, s); δC 52.30 (-OCH3), 
56.01 (-OCH3) and 62.88 (-OCH3)]. The 
13C NMR of 104 revealed three oxygenated 
carbons [δC 154.73 (C-5), 156.18 (C-9) and 157.92 (C-7)], supporting the phloroglucinol 
moiety of compound 103. 13C NMR spectrum showed that there are two aryl-methoxyl 
groups (δC 56.01 and 62.88), and one of which is di-ortho substituted [δC 62.88 (5-
OCH3)]. These results are consistent with the postulated structure of 103. The NOESY 
experiment showed correlation between 7-OMe with H-8, and between 5-OMe with H-4 
(see Figure 17). This shows that the postulated structure of 103 is indeed correct. This 
was further supported from the HMBC experiment. The 3J HMBC correlations of 5-OMe 
protons (δH 3.80)/C-5 (δC 154.73) and that of 7-OMe protons (δH 3.78)/C-7 (δC 157.92) 
established that the two methoxyl groups was attached to C-5 and C-7 respectively. Thus 
104 was confirmed to be Methyl 5, 7-dimethoxy-2, 2-dimethyl-2H-chromene-6-
carboxylate.  104 has not been isolated from natural or synthetic source. This is the first 





















Table 15 1H (500 MHz) and 13C (125 MHz) NMR data for Methyl 5, 7-dimethoxy-2, 2-
dimethyl-2H-chromene-6-carboxylate (104) in CHCl3. (J in Hz in parentheses) 





















5.51 d, J = 10.1 Hz 





























C-10, C-12, C-13 












































2,2-Dimethyl-2H-chromenes are widespread in many higher plants, especially in 
Asteraceae [101, 102] and Rutaceae [103]. However, they are rare liverwort constituents. The 
only chromene derivatives that have been reported are structural variations of prenylated 
bibenzyls in which a prenyl side chain of the bibenzyl is cyclised to give 2,2-
dimethylchromene derivatives.  
 
103 along with its precursor, methyl 2,4,6-trihydroxy-3-(3’-methyl-2’-butenyl)benzoate 
(105), have also been reported from  Garcinia nigrolineata [111] and the liverwort 










The biosynthesis route of 103 in Leptoscyphus expansus (Lehm.) Grolle has not been 
studied yet. However, it may involve the acetate pathway leading to the formation of an 
aromatic polyketide phloracetophenone (106), which in turn undergo oxidation, 
methylation by S-adenosylmethionine (SAM) and prenylation by isopentenyl 
pyrophosphate (IPP) leading to the formation of methyl 2,4,6-trihydroxy-3-(3’-
butenyl)benzoate (107).  The prenyl group tends to cyclize leading to the corresponding 
chroman derivative [109]. The cyclization of a prenyl side chain with the phenol group had 
been postulated to involve an intermediate epoxide, so that nucleophilic attack of the 
phenol on to the epoxide group might lead to formation of six-membered pyran 
heterocycles as commonly encountered in natural products (see Figure 19). The final step 
involves dehydration leading to the formation of the corresponding chromene. Although 
the reactions of Figure 21 offer a convenient rationalization for cyclization, epoxide 

























































Figure 19 Possible synthetic pathway of Methyl 5, 7-dihydroxy-2, 2-dimethyl-2H-
chromene-6-carboxylate (103) 
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The 2H-chromenes constitute an important family of oxygenated heterocylcles whose 
interesting photochromic properties only began to be systematically studied in the last 
decade [105]. Photochromism is a reversible transformation of a chemical species induced 
in one or both directions by absorption of electromagnetic radiation between two forms. 
The photochromism of 2H-chromenes involves a photoinduced breaking of the C(sp3)—
O bond of the pyran ring leading to an equilibrium between the closed form  and a set of 
stereoisomers of the open form of variable stabilities, constituting a system with a distinct 
absorption spectrum, generally in the visible range. The system reverts through a thermal 
pathway to its original closed form (Figure 20) [105]. One of the applications of 
photochromism is in photochromic spectacles that darken in the sun and recover their 
transparency in diffuse light. The first commercial glasses were made of glass lenses 
impregnated with inorganic (mainly silver) salts but in recent years, organic 
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2, 2-dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) chromene (108) 
Compound 108 was obtained as yellow solid. The EI-MS of 108 showed a molecular ion 
[M]+ at m/z 338.0, consistent with the molecular formula C21H22O4, which is confirmed 
by HREI-MS (found [M]+ at m/z 338.1517, requires 338.1512). The UV spectrum 
showed absorption at 231 and 282 nm. The IR spectrum indicates the presence of 
carboxyl group [3450 cm-1 (OH) and 1727 cm-1 (C=O)] and benzene ring (1596 and 1459 












5 ''  
108 
 
The 1H NMR spectrum of 108 (see Table 16) showed an AB system at δH 5.63 (1H, d, J 
= 10.1 Hz) and δH 6.65 (1H, d, J = 10.1 Hz), an intense singlet at δH 1.54 (6H), referring 
to two methyl groups, one aromatic hydrogen at δH 6.24 (1H. s). These data suggested a 
chromene skeleton with a penta-substituted aromatic ring system. This was further 
supported by 13C NMR spectrum [a carbinolic carbon at δC 79.54 (C), two methine sp
2
 
carbons at δC 128.01 and 116.53, two equivalent methyl groups at δC 27.51, six aromatic 
carbons at  δC 107.99 (CH), 108.23 (C), 110.14 (C), 148.52 (C), 152.83 (C) and 156.89 
(C), with the latter two signals indicative of oxygenated sp2 carbons]. The 1H and 13C 
NMR spectra also showed the presence of a mono-substituted benzene ring [δH 7.25-7.27 




125.77 (C-4”)], two benzylic methylenes [δH 2.92 (2H, s, H2-β) and 3.31 (2H, s, H2-α); δC 
37.65 (C-β) and 38.65 (C-α)], and one aryl-methoxyl group [δH 3.77 (3H, s); δC 55.64 (-
OCH3)]. 
 
HMBC confirmed the structure of 108 (see Table 16 and Figure 21). The 3J HMBC 
correlations of H-4 (δH 6.65)/C-5 (δH 156.89) and C-9 (δC 152.83), and that of H-3 (δH 
5.63)/C-10 (δH 108.23) established the fusion of the chromene ring at C-9 and C-10 with 
an ether linkage at C-9. The singlet aromatic proton was attributed to H-6 according to 2J 
correlations with C-5 (δC 156.89) and C-7 (δC 148.52), as well as 
3
J correlations with C-8 
(δC 110.14), C-10 (δC 108.23) and C-α (δC 38.65). The benzylic methylene proton H-α 
showed correlation with C-6 (δC 107.99) (
3
J), C-7 (δC 148.52) (
2
J) and C-8 (δC 110.14) 
(3J) showed that the benzylic group is attached to C-7. H-β (δH 2.92) showed 
2
J 
correlation with C-1” (δC 142.02) as well as 
3
J correlations with C-2”/C-6” (δC 128.76) 
indicated that the monosubstituted benzene ring was attached to the benzylic methylene 
carbon C-β through C-1”. HMBC correlation also revealed that the methoxyl group is 
attached to C-5. Since the methoxyl group appeared at δC 55.64, C-6 must be 
unsubstituted. Thus the remaining carboxyl group must be attached to C-8. Further prove 
come from NOESY experiment (see Figure 22). The NOESY experiment showed 
correlation between 5-OMe proton and H-6 showed that the methoxyl group is attached 
to C-5. The structure of 108 was further confirmed by X-ray crystallography (see Figure 





Table 16 1H (500 MHz) and 13C (125 MHz) NMR data for 2,2-dimethyl-5-methoxy-8-
carboxy-7-(2-phenylethyl) chromene (108) in CHCl3. (J in Hz in parentheses) 
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Figure 22 Selected NOE correlations of 2,2-dimethyl-5-methoxy-8-carboxy-7-(2-
phenylethyl) chromene (108) 
 
 




This bibenzyl was formed from phenylpropanoids pathway [112]. However, the 
biosynthesis mechanism of this compound remains unknown. The following discussion is 
the possible biosynthetic pathway of the compound (Figure 24). Phenylalanine (109) was 
converted by phenyl alanine lyase (PAL) to cinnamic acid (110) [112]. Subsequently 
cinnamic acid was activated as its coenzyme A thioester (111) and condenses with three 
molecule of malonyl-CoA followed by dehydration and tautomerism to form the bicyclic 
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112. Hydration and prenylation of 112 yields 2-carboxy-3,5-dihydroxy-4-(3-methyl-2-
butenyl)-bibenzyl (114). 114 was then methylated to form 2-carboxy-3-hydroxy-5-
methoxy-4-(3-methyl-2-butenyl)-bibenzyl (115), which will then cyclised to yield the 
product 2, 2-dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) Chromene (108). The 
ester 116 was shown to be easily converted to its corresponding chroman upon treatment 
under acidic condition (Figure 25) support the fact that prenyl groups tend to cyclised 
leading to the corresponding chromene derivative [109]. The precursor 114 and 115 were 






























Figure 24 Possible biosynthetic pathway of 2,2-dimethyl-5-methoxy-8-carboxy-7-(2-












































3.4.1 General Experimental 
Chromatography 
Thin layer Chromatography (TLC) was carried out on precoated glass TLC plates—
normal phase (Merck, Kieselgel 60F254, 250 µm), C18 silica (Whatman, KC18F, 200 µm), 
DIOL silica (Merck, HPTLC-Fertigplatten DIOL F254S). Analytical TLC plates were 
visualized with UV light (254 nm) and then stained with I2 vapor or ethanolic FeCl3 (for 
detection of phenolic compounds). Column chromatography was carried out on silica gel 
(40-63 µm, Merck) or on C18 (25-40 µm, Merck) and DIOL (Merck, Lichroprep 40-63 
µm) bonded phases. For gel permeation column chromatography (GPC), Sephadex LH-
20 (MeOH:CH2Cl2 = 1:1 as eluent) was used.  
 
Spectroscopy 
UV spectra were obtained on a SHIMADZU 1601PC UV-Visible spectrophotometer. IR 
spectra were measured with the Varian Excalibur Series 3100 FT-IR. Electron impact 
(EI) mass spectra were obtained on a VG Micromass 7035 instrument at 70eV. Accurate 
mass electron impact (HR-EI) mass spectra were obtained on a Finnigan MAT95XL-T 
instrument at 20 KV with 3-Nitrobenzyl alcohol (3NBA) as the matrix. NMR spectra 
were measured using Bruker DPX 300 [300 MHz (1H) and 75 MHz (13C)], Bruker AMX 
500 [500 MHz (1H) and 125 MHz (13C)] or Bruker DRX 500 [500 MHz (1H) and 125 
MHz (13C)] instruments using CDCl3 as a solvent (unless otherwise specified). The 
solvent peaks acted as the internal standards. For CDCl3, δH 7.26, δC 77.0; for acetone-d6, 
δH 2.05, δC 30.5. Multiplicities were determined using the DEPT pulse sequence or 
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deduced from 2D HMQC. Coupling constants (J) were measured in Hertz (Hz). 1D and 
2D NMR standard microprograms were supplied by Bruker. X-ray diffraction for single 
crystals structures was measured on a Bruker AXS SMART APEX CCD X-Ray 
Diffractometer. Sadabs (Sheldrick 2001) was used for absorption corrections, λ = 
0.71073 Å.  
 
Reaction  
Methylation of phenolic compounds with CH3I and K2CO3 
The compound along with CH3I and anhydrous K2CO3 were added to A.R. grade acetone 
and the mixture was refluxed until TLC indicated that the reaction was complete. After 
the removal of solvent and excess CH3I under vacuum, the residue was separated by 
column chromatography in Pasteur pipette using acetone as eluent. The eluent gave the 
product after drying and concentration. 
 
3.4.2 Leptoscyphus expansus (Lehm.) Grolle 
Plant material and Extraction 
Leptoscyphus expansus (Lehm.) Grolle was collected in Tierra del Fuego, Argentina in 
March 1997. The liverwort (150 g) was homogenized with dichloromethane (CH2Cl2) 
and kept for about 2 weeks in the dark at room temperature. The solvent was changed 
with fresh solvent at 5 days interval. Filtration and removal of solvent under vacuum 





The crude extract was chromatographed on a silica gel column eluted with a solvent 
gradient (iso-octane-acetone-methanol) to afford 6 fractions. 
 
Fraction 1 
The TLC and 1H NMR results of this fraction (1 g) showed that it did not contain 
interesting metabolites and therefore were not investigated further. 
 
Fraction 2 
The fraction (ca. 2.1 g) was chromatographed on Sephadex LH-20 to afford a mixture 
(0.7 g). The mixture was further separated by silica gel column (20 % EtOAc-isooctane) 
and reversed phase column chromatography (C18, 80 % MeOH-H2O) successively to give 
5-hydroxyl-7-methoxyflavone (92) (12.5 mg) and Methyl 5, 7-dihydroxy-2, 2-dimethyl-
2H-chromene-6-carboxylate (103) (14.5 mg). 
 
Fraction 3 
The third fraction (1.5 g) was chromatographed on Sephadex LH-20 to afford a mixture 
(0.5 g). The mixture was further separated by silica gel column (30 % EtOAc-isooctane) 
and DIOL (30 % CH2Cl2-isooctane) to afford two compounds, 5-Hydroxy-7,4’-
dimethoxyflavone (95) (2 mg) and 2, 2-dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) 






The fourth fraction (1.6 g) was chromatographed on Sephadex LH-20 to afford a fraction 
(ca. 685 mg), which was further chromatographed on silica gel column (60 % EtOAc-
isooctane) to afford one compound, 5, 6, 7-Trimethoxyflavone (Baicalein trimethyl ether) 
(102) (137 mg). 
 
Fraction 5 
The fifth fraction (1.5 g) was chromatographed on Sephadex LH-20 to afford a fraction 
(450 mg), which was further chromatographed on silica gel column (60 % EtOAc-
isooctane) and DIOL (30 % EtOAc-isooctane) to give a compound, 5,7-
Dimethoxyflavone (97) (211.2 mg). 
 
Fraction 6 
The sixth fraction (1 g) was chromatographed on Sephadex LH-20 to afford a fraction 
(400 mg), which was further chromatographed on silica gel column (60 % EtOAC-
isooctane) and reversed phase column (80 % MeOH-H2O) to afford a compound, 5-
Hydroxy-6, 7-dimethoxyflavone (98) (20 mg). 
 
5-Hydroxy-7-methoxyflavone (92) (12.5 mg) Yellow solid; UV (methanol) λmax nm: 
269, 306 and; FI-IR νmax (CHCl3) cm
-1: 3408, 1668, 1600, 1587 and 1456, 1200 and 
1160, 762 and 680; EI-MS m/z (rel. int.): 269 [M + H]+ (18), 268 [M]+ (100), 267 [M – 
H]+ (11), 239 [M-C-OH]+  (33), 225 [M-C-OCH3]
+ (11); HREI-MS: m/z 268.0730 
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(C16H12O4 requires m/z 268.0732); 
1H NMR (300 MHz, CDCl3): δ 12.71 (1H, br s, 5-
OH), 7.88 (2H, m, H-2’ and H-6’), 7.53 (3H, m, H-3’, H-4’ and H-5’), 6.66 (1H, s, H-3), 
6.49 (1H, d, J = 2.07 Hz, H-8), 6.36 (1H, d, J = 2.07 Hz) and 3.88 (3H, s, 7-OCH3); 
13C 
NMR (75 MHz, CDCl3) and HMBC (125 MHz): δC 182.48 (C-4), 165.60 (C-7), 163.98 
(C-2), 162.17 (C-5), 157.78 (C-9),  131.81 (C-4’), 131.30 (C-1’), 129.06 (C-3’ and C-5’), 
126.27 (C2’ and C-6’), 105.85 (C-3), 105.69 (C-10), 98.19 (C-6), 92.66 (C-8), and 55.79 
(7-OCH3). 
 
5-Hydroxy-7,4’-dimethoxyflavone (95) (2 mg). Yellow solid; UV (methanol) λmax nm: 
272, 324 and; FI-IR νmax (CHCl3) cm
-1: 3405, 3075, 2925, 1660, 1600, 1587 and 1445, 
1182 and 1035; EI-MS m/z (rel. int.): 299 [M + H]+ (13), 298 [M]+ (100), 297 [M – H]+ 
(11), 269 [M-C-OH]+  (30), 255 [M-C-OCH3]
+ (12); HREI-MS: m/z 298.0841 (C17H14O5 
requires m/z 298.0837); 1H NMR (500 MHz, CDCl3): δ 7.85 (2H, m, H-2’ and H-6’), 
7.02 (3H, m, H-3’, H-4’ and H-5’), 6.58 (1H, s, H-3), 6.49 (1H, d, J = 2.07 Hz, H-8), 6.37 
(1H, d, J = 2.07 Hz), 3.90 (3H, s, 4’-OCH3 or 7-OCH3) and 3.88 (3H, s, 4’-OCH3 or 7-
OCH3); 
13C NMR (125 MHz, CDCl3): δC 182.47 (C-4)], 165.40 (C-7), 163.92 (C-2), 
162.50 (C-4’), 162.13 (C-5), 157.61 (C-9), 128.05 (C-2’ and C-6’), 123.38 (C-1’), 114.50 
(C-3’ and C-5’), 105.50 (C-10), 104.21 (C-3),  98.04 (C-6), 92.63 (C-8), 55.79 (-OCH3), 
55.53 (-OCH3). 
 
5,7-Dimethoxyflavone (97) (211.2 mg). Yellow solid; UV (methanol) λmax nm: 264, 307 
and; FI-IR νmax (CHCl3) cm
-1: 3012, 1643, 1610, 1600, and 1460, 1213 and 1117, 3012; 
EI-MS m/z (rel. int.): 283 [M + H]+ (18), 282 [M]+ (100), 281 [M – H]+ (62), 264 [M-
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H2O]
+  (7), 253 (48), 236 (47), 224 (13), 209 (28); HREI-MS: m/z 282.0882 (C17H14O4 
requires m/z 282.0888); 1H NMR (300 MHz, CDCl3): δ 7.81 (2H, m, H-2’ and H-6’), 
7.45 (3H, m, H-3’, H-4’ and H-5’), 6.63 (1H, s, H-3), 6.52 (1H, d, J = 2.0 Hz, H-8), 6.31 
(1H, d, J = 2.0 Hz, H-6), 3.89 (3H, s, 5-OCH3 or 7-OCH3) and 3.86 (3H, s, 5-OCH3 or 7-
OCH3); 
13C NMR (75 MHz, CDCl3): δC 177.66 (C-4), 164.06 (C-7), 161.0 (C-2), 160.71 
(C-5), 159.75 (C-9), 131.24 (C-1’), 131.12 (para, C-4’), 128.79 (meta, C-3’ and C-5’), 
125.82 (ortho, C-2’ and C-6’), 108.69 (C-3), 108.67 (C-10), 96.09 (C-6), 92.73 (C-8), 
56.19 (-OCH3), and 55.64 (-OCH3). 
 
5-Hydroxy-6, 7-dimethoxyflavone (98) (20 mg). Yellow solid; UV (methanol) λmax nm: 
280, 310 and; FI-IR νmax (CHCl3) cm
-1: 3515, 1685, 1630, 1600, and 1456, 1200 and 
1158, 780 and 685; EI-MS m/z (rel. int.): 299 [M + H]+ (8), 298 [M]+ (100), 297 [M – 
H]+ (10), 283 [M-CH3]
+  (70), 269 (11), 255(10), 181 (15), 153 (36); HREI-MS: m/z 
298.0837 (C17H14O5 requires m/z 298.0841); 
1H NMR (500 MHz, CDCl3): δ 12.67 (1H, 
br s, 5-OH), 7.89 (2H, m, H-2’ and H-6’), 7.53 (3H, m, H-3’, H-4’ and H-5’), 6.68 (1H, s, 
H-3), 6.57 (1H, s, H-8), 3.97 (3H, s, 6-OCH3 or 7-OCH3) and 3.93 (3H, s, 6-OCH3 or 7-
OCH3); 
13C NMR (125 MHz, CDCl3): δC 182.72 (C-4), 163.96 (C-2), 158.90 (C-7), 
153.32 (C-9), 153.02 (C-5), 132.68 (C-6), 131.83 (C-4’), 131.29 (C-1’), 129.08 (C-3’ and 
C-5’), 126.24 (C2’ and C-6’),  106.29 (C-10), 105.61 (C-3), 90.63 (C-8), 60.85 (-OCH3) 
and 56.32 (-OCH3).  
 
5, 6, 7-Trimethoxyflavone (Baicalein trimethyl ether) (102) (137 mg). Yellow solid; 
UV (methanol) λmax nm: 263, 301 and; FI-IR νmax (CHCl3) cm
-1: 3000, 2945, 1625, 1595, 
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and 1348, 1232 and 1118, 770 and 690; EI-MS m/z (rel. int.): 313 [M + H]+ (5), 312 [M]+ 
(13), 297 [M – CH3]
+ (100), 284 [M-CO]+  (10), 269 (14), 254 (16), 167 (12); HREI-MS: 
m/z 312.0998 (C18H16O5 requires m/z 312.0993); 
1H NMR (300 MHz, CDCl3): δ 7.83 
(2H, m, H-2’ and H-6’), 7.46 (3H, m, H-3’, H-4’ and H-5’), 6.78 (1H, s, H-3), 6.65 (1H, 
d, s, H-8), 3.93 (3H, s, 5-OCH3 , 6-OCH3 or 7-OCH3),  3.92 (3H, s, 5-OCH3 , 6-OCH3 or 
7-OCH3) and 3.86 3.93 (3H, s, 5-OCH3 , 6-OCH3 or 7-OCH3); 
13C NMR (75 MHz, 
CDCl3): δC 177.42 (C-4), 161.23 (C-2), 157.80 (C-7), 154.43 (C-9), 152.25 (C-5), 140.22 
(C-6), 131.50 (C-1’), 131.22 (C-4’), 128.80 (C-3’ and C-5’), 125.84 (C2’ and C-6’), 
112.55 (C-10), 107.94 (C-3), 96.16 (C-8), 62.01 (5- or 6-OCH3), 61.34 (5- or 6-OCH3), 
56.16 (7-OCH3). 
 
Methyl 5, 7-dihydroxy-2, 2-dimethyl-2H-chromene-6-carboxylate (103) (14.5 mg). 
Yellow oil; UV (methanol) λmax nm: 262, 333 and; FI-IR νmax (CHCl3) cm
-1: 3437, 3022, 
2976 1649, 1588, 1461, and 1368, 1213, 1156; EI-MS m/z (rel. int.): 251 [M + H]+ (5), 
250 [M]+ (20), 235 [M – CH3]
+ (37), 217 (4), 203[M-2xCH3-OH]
+ (100), 175 (2), 147 (1) 
135 (2), 91 (3), 69 (5), 55 (2); HREI-MS: m/z 250.0840 (C13H14O5 requires m/z 
250.0837); 1H NMR (500 MHz, CDCl3): δ 6.61 (1H, d, J = 10.11 Hz, H-4), 5.96 (1H, s, 
H-8), 5.46 (1H, d, J = 10.11 Hz, H-3), 4.03 (3H, s, 11-OCH3), 1.42 (6H, s, H3-12 and H3-
13); 13C NMR (125 MHz, CDCl3) and HMBC (125 MHz, CDCl3): δC 169.79 (C-11), 
160.60 (C-5, C-7 and C-9), 125.90 (C-3), 115.91 (C-4), 102.31 (C-10), 96.75 (C-8), 
93.51 (C-6), 77.74 (C-2), 52.48 (-OCH3) and 28.29 (C-12 and C-13). 
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Methylation of Methyl 5, 7-dihydroxy-2, 2-dimethyl-2H-chromene-6-carboxylate 
(104). Seven milligram of 103 was reacted with iodomethane (CH3I) in boiling acetone in 
the presence of excess potassium carbonate anhydrous (K2CO3). The reaction was carried 
out under reflux at 60 oC and was monitored with TLC analysis. CH3I was added to the 
reaction mixture in 30 minutes interval until the reaction was completed. The product, 
methyl 5,7-dimethoxy-2,2-dimethyl-2H-chromene-6-carboxylate (104) was separated 
from the reaction mixture by column chromatography in a Pasteur pipette using acetone 
as the mobile phase. Only the product 104 was eluted and it was pure (based on TLC and 
1H NMR analysis). 6.8 mg of product was obtained. 
 
Methyl 5,7-dimethoxy-2,2-dimethyl-2H-chromene-6-carboxylate (104) (6.8 mg). 
Yellow oil; UV (methanol) λmax nm: 232, 286 and; FI-IR νmax (CHCl3) cm
-1: 3022, 2952, 
1645, 1607, 1466, and 1370, 1213 and 1156; EI-MS m/z (rel. int.): 279 [M + H]+ (2), 278 
[M]+ (16), 277 [M-H]+, 263 [M – CH3]
+ (100), 247 [M-OCH3]
+ (6), 217 (12), 189 (5), 
161 (8) 116 (5), 44 (17); HREI-MS: m/z 278.1144 (C15H18O5 requires m/z 278.1149); 
1H 
NMR (500 MHz, CDCl3): δ 6.48 (1H, d, J = 10.1 Hz, H-4), 6.20 (1H, s, H-8), 5.51 (1H, 
d, J = 10.1 Hz, H-3), 3.89 (3H, s, 11-OCH3), 3.80 (3H, s, 5-OCH3), 3.78 (3H, s, 7-OCH3) 
and 1.42 (6H, s, H3-12 and H3-13); 
13C NMR (125 MHz, CDCl3) and HMBC (125 MHz, 
CDCl3): δC 166.73 (C-11), 157.92 (C-7), 156.18 (C-9), 154.73 (C-5), 127.72 (C-3), 
116.48 (C-4), 76.81 (C-2), 110.19 (C-6), 107.83 (C-10), 96.16 (C-8), 62.88 (-OCH3), 




2, 2-dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) chromene (108) (46.1 mg). 
White solid; ; UV (methanol) λmax nm: 231, 282 and; FI-IR νmax (CHCl3) cm
-1: 3450 (br), 
2977, 2934, 1727, 1596, 1459, and 1373, 1115 and 1040; EI-MS m/z (rel. int.): 339 [M + 
H]+ (2), 338 [M]+ (6), 323 [M – CH3]
+ (48), 305 [M-CH3-H2O]
+ (7), 294 [M-CO2]
+ (12), 
279 [M-CH3-CO2]
+ (100), 188 (44) 145 (8), 115 (5), 91 (6); HREI-MS: m/z 338.1517 
(C21H22O4 requires m/z 338.1512); 
1H NMR (500 MHz, CDCl3): δ 7.27 (2H, m, H-3” and 
H-5”), 7.25 (2H, m, H-2” and H-6”), 7.17 (1H, m, H-4”), 6.65 (1H, d, J = 10.1 Hz, H-4), 
6.24 (1H, s, H-6), 5.63 (1H, d, J = 10.1 Hz, H-3), 3.77 (3H, s, 5-OCH3), 3.31 (2H, m, H2-
α), 2.92 (2H, m, H2-β) and 1.54 (6H, s, H3-1’ and H3-2’); 
13C NMR (125 MHz, CDCl3) 
and HMBC (125 MHz, CDCl3): δC 165.58 (Carboxyl Carbon), 156.89 (C-5), 152.83 (C-
9), 148.52 (C-7), 142.02 (C-1”), 128.76 (C-2” and C-6”), 128.22 (C-3” and C-5”), 128.01 
(C-3), 125.77 (C-4”), 116.53 (C-4), 110.14 (C-8), 108.23 (C-10), 107.99 (C-6), 79.54 (C-
2), 55.64 (-OCH3), 38.65 (C-α), 37.65 (C-β), and 27.51 (C-1’ and C-2’). 
 
 
Crystallographic data for 2, 2-dimethyl-5-methoxy-8-carboxy-7-(2-phenylethyl) 
chromene 
C21H22O4, Mr 338.39, orthorhombic, space group Pna2(1), a = 20.6556(8) Å, b = 9.0133(4) 
Å, c = 19.5612(8) Å, α = β = γ = 90o, V = 1335.2(2) Å, Z = 8, Density (calculated) = 1.234 
Mg/m3, F(000) = 1440, λ = 0.71073 Å, µ = 0.085 mm-1. Data were collected using a 
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